USRE48059E1 - Piperazine-substituted benzothiophenes for treatment of mental disorders - Google Patents

Piperazine-substituted benzothiophenes for treatment of mental disorders Download PDF

Info

Publication number
USRE48059E1
USRE48059E1 US15/815,650 US200615815650A USRE48059E US RE48059 E1 USRE48059 E1 US RE48059E1 US 200615815650 A US200615815650 A US 200615815650A US RE48059 E USRE48059 E US RE48059E
Authority
US
United States
Prior art keywords
group
lower alkyl
alkyl group
benzo
thiophen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/815,650
Other languages
English (en)
Inventor
Hiroshi Yamashita
Nobuaki Ito
Shin Miyamura
Kunio Oshima
Jun Matsubara
Hideaki Kuroda
Haruka Takahashi
Satoshi Shimizu
Tatsuyoshi Tanaka
Yasuo Oshiro
Shinichi Taira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36645750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE48059(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to US15/815,650 priority Critical patent/USRE48059E1/en
Application granted granted Critical
Publication of USRE48059E1 publication Critical patent/USRE48059E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • the present invention relates to a novel heterocyclic compound.
  • WO2004/026864A1 discloses that a carbostyril derivative represented by the general formula:
  • A′ represents —(CH 2 ) m CH 2 —, —(CH 2 ) m O—, etc.
  • m represents an integer of 1 to 4
  • R A represents a hydrogen atom, a C 1-4 alkyl group which may be substituted with 1 to 3 fluorine atoms, etc.
  • D 2 receptor antagonist activity and serotonin 2A (5-HT 2A ) receptor antagonist activity and it is effective for treatment of schizophrenia and other central nervous system disorders).
  • WO 2005/019215 A1 discloses the compounds represented by the following formula:
  • A is —(CH 2 ) m CH 2 —, —(CH 2 ) m O— or the like; m is an integer of 2 to 5; D is N, C or the like; Z and Q are independently N, C or CH, provided that at least one of Z and Q is N; X and Y are independently C, N or the like, and the bond between X and Y is a single or double bond; R 1 is hydrogen, (C 1 -C 3 )alkyl group or the like; R 4 , R 5 , R 6 and R 7 each represents hydrogen, alkyl group or the like; and G represents a group of monocyclic or bicyclic compound), which bind to dopamine D 2 receptors.
  • WO 2005/019215 A1 teaches that some compounds disclosed therein have an activity as partial agonists of D 2 receptors or an activity as antagonists of D 2 receptors, and may be effective for the treatment of schizophrenia and other central nervous system.
  • WO 2005/019215 A1 does not specifically disclose the compounds of the present invention.
  • An object of the present invention is to provide an antipsychotic drug which has a wider treatment spectrum, less side effects and excellent tolerability and safety as compared with well-known typical and atypical antipsychotic drugs.
  • the present inventors have conducted intensive studies on the above-described problem and consequently succeeded in synthesizing a novel compound which has dopamine D 2 receptor partial agonist activity (D 2 receptor partial agonist activity), serotonin 5-HT 2A receptor antagonist activity (5-HT 2A receptor antagonist activity) and adrenalin ⁇ 1 receptor antagonist activity ( ⁇ 1 receptor antagonist activity) and further has serotonin uptake inhibitory effect (or serotonin reuptake inhibitory effect) together in addition to these effects.
  • D 2 receptor partial agonist activity dopamine D 2 receptor partial agonist activity
  • serotonin 5-HT 2A receptor antagonist activity (5-HT 2A receptor antagonist activity)
  • adrenalin ⁇ 1 receptor antagonist activity ⁇ 1 receptor antagonist activity
  • the present invention has been completed based on this finding.
  • the present invention provides a heterocyclic compound represented by the general formula (1):
  • the ring Q may have at least one substituent selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a hydroxy group, a lower alkoxy group, a halogenated lower alkyl group, an aryl group, an aryl lower alkyl group, an aryl lower alkoxy group, an arylcarbonyl group, a lower alkenyloxy group, a lower alkanoyl group, a lower alkanoyloxy group, a cycloalkyl group, a cycloalkyl lower alkyl group, a halogen atom, a carbamoyl group which may have a lower alkyl group, a carboxy group, a lower alkoxycarbonyl group, an amino group which may have a lower alkanoyl group, a nitro group, a hydroxy lower alkyl group, an amino lower alkyl group which may have a lower alkyl group
  • R 2 represents a hydrogen atom or a lower alkyl group
  • A represents —O-A 1 - (wherein A 1 represents an alkylene group which may be substituted with a hydroxy group (wherein the alkylene group may contain one oxygen atom) or a lower alkenylene group) or a lower alkylene group;
  • the ring Q represents a bicyclic group selected from the group consisting of:
  • the present invention provides a heterocyclic compound represented by the general formula (1),
  • ring Q represents a bicyclic group selected from the group consisting of:
  • the ring Q may have 1 to 3 substituents selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a hydroxy group, a lower alkoxy group, a halogenated lower alkyl group, a phenyl group, a phenyl lower alkyl group, a naphthyl lower alkyl group, a phenyl lower alkoxy group, a naphthyl lower alkoxy group, a benzoyl group, a lower alkenyloxy group, a lower alkanoyl group, a lower alkanoyloxy group, a cyclo C3-C8 alkyl group, a cyclo C3-C8 alkyl lower alkyl group, a halogen atom, a carbamoyl group which may have a lower alkyl group, a carboxy group, a lower alkoxycarbonyl group, an amino group which may have lower
  • A represents —O-A 1 - (wherein. A 1 represents a C1-C6 alkylene, group which may be substituted with a hydroxy group (wherein the alkylene group may contain one oxygen atom)), or a salt thereof.
  • the present invention provides a heterocyclic compound represented by the general formula (1), wherein the ring Q represents a bicyclic group selected from the group consisting of:
  • the ring Q may have 1 to 3 substituents selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a hydroxy group, a lower alkoxy group, a halogenated lower alkyl group, a phenyl group, a phenyl lower alkyl group, a naphthyl lower alkyl group, a phenyl lower alkoxy group, a naphthyl lower alkoxy group, a benzoyl group, a lower alkenyloxy group, a lower alkanoyl group, a lower alkanoyloxy group, a cyclo C3-C8 alkyl group, a cyclo C3-C8 alkyl lower alkyl group, a halogen atom, a carbamoyl group which may have a lower alkyl group, a carboxy group, a lower alkoxycarbonyl group, an amino group which may have
  • A represents —O-A 1 - (wherein A 1 represents a C1-C6 alkylene group which may be substituted with a hydroxy group (wherein the alkylene group may contain one oxygen atom)), or a salt thereof.
  • the present invention provides a heterocyclic compound represented by the general formula (1), wherein the ring Q represents a bicyclic group selected from the group consisting of:
  • the ring Q may have 1 to 3 substituents selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a hydroxy group, a lower alkoxy group, a halogenated lower alkyl group, a phenyl group, a phenyl lower alkyl group, a naphthyl lower alkyl group, a phenyl lower alkoxy group, a naphthyl lower alkoxy group, a benzoyl group, a lower alkenyloxy group, a lower alkanoyl group, a lower alkanoyloxy group, a cyclo C3-C8 alkyl group, a cyclo C3-C8 alkyl lower alkyl group, a halogen atom, a carbamoyl group which may have a lower alkyl group, a carboxy group, a lower alkoxycarbonyl group, an amino group which may have
  • the present invention provides a heterocyclic compound represented by the general formula (1), wherein the ring Q represents a bicyclic group selected from the group consisting of:
  • the ring Q may have 1 to 3 substituents thereon selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a hydroxy group, a lower alkoxy group, a halogenated lower alkyl group, a phenyl group, a phenyl lower alkyl group, a naphthyl lower alkyl group, a phenyl lower alkoxy group, a naphthyl lower alkoxy group, a benzoyl group, a lower alkenyloxy group, a lower alkanoyl group, a lower alkanoyloxy group, a cyclo C3-C8 alkyl group, a cyclo C3-C8 alkyl lower alkyl group, a halogen atom, a carbamoyl group which may have a lower alkyl group, a carboxy group, a lower alkoxycarbonyl group, an amino group which may
  • A represents a lower alkylene group, or a salt thereof.
  • the present invention provides a heterocyclic compound represented by the general formula (1), wherein the ring Q represents a bicyclic group selected from the group consisting of:
  • the ring Q may have 1 to 3 substituents selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a hydroxy group, a lower alkoxy group, a halogenated lower alkyl group, a phenyl group, a phenyl lower alkyl group, a naphthyl lower alkyl group, a phenyl lower alkoxy group, a naphthyl lower alkoxy group, a benzoyl group, a lower alkenyloxy group, a lower alkanoyl group, a lower alkanoyloxy group, a cyclo C3-C8 alkyl group, a cyclo C3-C8 alkyl lower alkyl group, a halogen atom, a carbamoyl group which may have a lower alkyl group, a carboxy group, a lower alkoxycarbonyl group, an amino group which may have
  • preferable compounds include a compound or a salt thereof selected from:
  • preferable compounds include a compound or a salt thereof selected from:
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a heterocyclic compound represented by the formula (1) or a salt thereof as an active ingredient mixed with a pharmaceutically acceptable carrier.
  • the pharmaceutical composition according to the present invention can be effectively used for the treatment or prevention of central nervous system disorders.
  • the pharmaceutical composition according to the present invention can be used as a pharmaceutical composition for treating or preventing central nervous system disorders selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar II type disorder; depression; endogenous depression; major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; agoraphobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; generalized anxiety disorder; acute stress disorder; hysteria; somatization disorder; conversion disorder; pain disorder; hypochondriasis; factitious disorder; dissociative disorder; sexual dysfunction; sexual desire disorder; sexual arousal disorder; erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep disorder; adjustment disorder; alcohol abuse; alcohol intoxication; drug addiction; stimulant intoxication; narcotism; anhe
  • the present invention provides a process for producing a pharmaceutical composition comprising mixing a heterocyclic compound represented by the above-described formula (1) or a salt thereof with a pharmaceutically acceptable carrier.
  • the present invention provides use of a heterocyclic compound represented by the above-described formula (1) or a salt thereof as a drug.
  • a heterocyclic compound represented by the above-described formula (1) or a salt thereof as a dopamine D 2 receptor partial agonist and/or a serotonin 5-HT 2A receptor antagonist and/or an adrenaline ⁇ 1 receptor antagonist and/or a serotonin uptake inhibitor (or a serotonin reuptake inhibitor).
  • the present invention provides a method for treating or preventing a central nervous system disorder comprising administering a compound represented by the above-described formula (1) or a salt thereof to human or animal.
  • the present invention provides a process for producing a heterocyclic compound represented by the above-described formula (1):
  • a linear or branched alkyl group having 1 to 6 carbon atoms can be mentioned. More specifically, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-ethylpropyl, isopentyl, neopentyl, n-hexyl, 1,2,2-trimethylpropyl, 3,3-dimethylbutyl, 2-ethylbutyl, isohexyl, 3-methylpentyl groups are included.
  • a linear or branched alkoxy group having 1 to 6 carbon atoms can be mentioned. More specifically, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, sec-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, 3-methylpentyloxy groups are included.
  • a linear or branched alkenyl group having 1 to 3 double bonds and 2 to 6 carbon atoms can be mentioned including the both of trans and cis configurations. More specifically, vinyl, 1-propenyl, 2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, 2-propenyl, 2-butenyl, 1-butenyl, 3-butenyl, 2-pentenyl, 1-pentenyl, 3-pentenyl, 4-pentenyl, 1,3-butadienyl, 1,3-pentadienyl, 2-penten-4-yl, 2-hexenyl, 1-hexenyl, 5-hexenyl, 3-hexenyl, 4-hexenyl, 3,3-dimethyl-1-propenyl, 2-ethyl-1-propenyl, 1,3,5-hexatrienyl, 1,3-hexadienyl, 1,
  • a linear or branched alkynyl group having 2 to 6 carbon atoms can be mentioned. More specifically, ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 2-pentynyl, 2-hexynyl groups are included.
  • halogen atom fluorine atom, chlorine atom, bromine atom and iodine atom can be mentioned.
  • halogenated lower alkyl group a lower alkyl group as illustrated above substituted with 1 to 7 halogen atoms, preferably 1 to 3 halogen atoms can be mentioned. More specifically, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, dichlorofluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 2-fluoroethyl, 2-chloroethyl, 3,3,3-trifluoropropyl, heptafluoropropyl, 2,2,3,3,3-pentafluoropropyl, heptafluoroisopropyl, 3-chloropropyl, 2-chloropropyl, 3-bromopropyl, 4,4,4-trifluorobutyl, 4,4,4,3,3-penta
  • aryl group for example, phenyl, biphenyl, naphthyl groups can be mentioned and as a substituent on the phenyl ring or naphthalene ring, a lower alkyl group (preferably linear or branched alkyl group having 1 to 6 carbon atoms) as illustrated above, lower alkoxy group (preferably linear or branched alkoxy group having 1 to 6 carbon atoms) as illustrated above, and phenyl, biphenyl, or naphthyl groups which may have 1 to 3 groups selected from a nitro group and a halogen atom are included.
  • a lower alkyl group preferably linear or branched alkyl group having 1 to 6 carbon atoms
  • lower alkoxy group preferably linear or branched alkoxy group having 1 to 6 carbon atoms
  • phenyl, biphenyl, or naphthyl groups which may have 1 to 3 groups selected from a nitro group and a halogen atom are included.
  • an aryl group examples include phenyl, 2- (or 3- or 4-)methylphenyl, 2- (or 3- or 4-) nitrophenyl, 2- (or 3- or 4-)methoxyphenyl, 2- (or 3- or 4-)chlorophenyl, biphenyl, ⁇ -naphthyl, ⁇ -naphthyl groups.
  • aryl lower alkyl group a lower alkyl group (preferably linear or branched alkyl group having 1 to 6 carbon atoms) as illustrated above which has 1 to 3, preferably one aryl group as illustrated above can be mentioned.
  • an aryl lower alkyl group examples include benzyl, 2- (or 3- or 4-)methylbenzyl, 2- (or 3- or 4-) nitrobenzyl, 2- (or 3- or 4-) methoxybenzyl, 2- (or 3- or 4-) chlorobenzyl, 1- (or 2-)phenylethyl, 1-methyl-1-phenylethyl, 1,1-dimethyl-2-phenylethyl, 1,1-dimethyl-3-phenylpropyl, ⁇ -naphthylmethyl, ⁇ -naphthylmethyl groups.
  • an aryl lower alkoxy group a lower alkoxy group (preferably linear or branched alkoxy group having 1 to 6 carbon atoms) as illustrated above which has 1 to 3, preferably one aryl group as illustrated above can be mentioned.
  • Specific examples of an aryl lower alkoxy group include benzyloxy, 2- (or 3- or 4-) methylbenzyloxy, 2- (or 3- or 4-) nitrobenzyloxy, 2- (or 3- or 4-)methoxy benzyloxy, 2-(or 3- or 4-) chlorobenzyl, 1- (or 2-)phenylethoxy, 1-methyl-1-phenyl ethoxy, 1,1-dimethyl-2-phenyl ethoxy, 1,1-dimethyl-3-phenyl propoxy, ⁇ -naphthylmethoxy, ⁇ -naphthylmethoxy groups.
  • an aryl group as illustrated above can be mentioned.
  • Specific examples of an arylcarbonyl group include benzoyl, 2- (or 3- or 4-)methylbenzoyl, 2- (or 3- or 4-) nitrobenzoyl, 2- (or 3- or 4-)methoxybenzoyl, 2- (or 3- or 4-)chlorobenzoyl, ⁇ -naphthoyl, ⁇ -naphthoyl groups.
  • a lower alkenyloxy group having a lower alkenyl group preferably a linear or branched alkenyloxy group having 1 to 3 double bonds and 2 to 6 carbon atoms
  • a lower alkenyloxy group having a lower alkenyl group preferably a linear or branched alkenyloxy group having 1 to 3 double bonds and 2 to 6 carbon atoms
  • vinyloxy More specifically included are vinyloxy, 1-propenyloxy, 1-methyl-1-propenyloxy, 2-methyl-1-propenyloxy, 2-propenyloxy, 2-butenyloxy, 1-butenyloxy, 3-butenyloxy, 2-pentenyloxy, 1-pentenyloxy, 3-pentenyloxy, 4-pentenyloxy, 1,3-butadienyloxy, 1,3-pentadienyloxy, 2-penten-4-yloxy, 2-hexenyloxy, 1-hexenyloxy, 5-hexenyloxy, 3-hexenyloxy, 4-hexenyloxy, 3,3-dimethyl-1-propenyloxy, 2-ethyl-1-propenyloxy, 1,3,5-hexatrienyloxy, 1,3-hexadienyloxy, 1,4-hexadienyloxy groups.
  • a linear or branched alkanoyl group having 1 to 6 carbon atoms can be mentioned. More specifically, formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, tert-butylcarbonyl, hexanoyl groups are included.
  • a linear or branched alkanoyloxy group having 1 to 6 carbon atoms can be mentioned. More specifically, formyloxy, acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, pentanoyloxy, tert-butylcarbonyloxy, hexanoyloxy groups are included.
  • a cycloalkyl group a cyclo C3-C8 alkyl group having 3 to 8 carbon atoms can be mentioned. Examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl groups.
  • a cycloalkyl lower alkyl group As a cycloalkyl lower alkyl group, a lower alkyl group as illustrated above which has 1 to 3, preferably one cycloalkyl group (preferably, cyclo C3-C8 alkyl group having 3 to 8 carbon atoms) as illustrated above can be mentioned.
  • carbamoyl group which may have a lower alkyl group a carbamoyl group which may have 1 to 2 lower alkyl group (preferably, alkyl group having 1 to 6 carbon atoms) as illustrated above can be mentioned. More specifically included are carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-methyl-N-ethylcarbamoyl groups.
  • lower alkoxycarbonyl group those having a lower alkoxy moiety as illustrated above, preferably a linear or branched alkoxycarbonyl group having 1 to 6 carbon atoms can be mentioned. More specifically included are methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, sec-butoxycarbonyl, n-pentyloxycarbonyl, neopentyloxy, n-hexyloxy carbonyl, isohexyloxycarbonyl, 3-methylpentyloxycarbonyl groups.
  • amino group which may have a lower alkanoyl group those having one lower alkanoyl group as illustrated above (preferably a linear or branched alkanoyl group having 1 to 6 carbon atoms) can be mentioned. More specifically, examples include amino, N-formylamino, N-acetylamino groups.
  • a hydroxy lower alkyl group a lower alkyl group (preferably, a linear or branched alkyl group having 1 to 6 carbon atoms) as illustrated above having 1 to 5, preferably 1 to 3 hydroxy groups can be mentioned. More specifically included are hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypropyl, 4-hydroxybutyl, 3,4-dihydroxybutyl, 1,1-dimethyl-2-hydroxyethyl, 5-hydroxypentyl, 6-hydroxyhexyl, 3,3-dimethyl-3-hydroxypropyl, 2-methyl-3-hydroxypropyl, 2,3,4-trihydroxybutyl, perhydroxyhexyl groups.
  • a lower alkyl group which may have a lower alkyl group
  • a lower alkyl group preferably, a linear or branched alkyl group having 1 to 6 carbon atoms
  • 1 to 5 preferably one amino group which may have 1 to 2 lower alkyl group (preferably, a linear or branched alkyl group having 1 to 6 carbon atoms) as illustrated above can be mentioned.
  • examples of such an amino lower alkyl group which may have a lower alkyl group include aminomethyl, 2-aminoethyl, 1-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 1,1-dimethyl-2-methyl-3-aminopropyl, N,N-dimethylaminomethyl, N-methyl-N-ethylaminomethyl, N-methylaminomethyl, 2-(N-methylamino)ethyl, 1-methyl-2-(N,N-dimethylamino)ethyl, 2-(N,N-dimethylamino)ethyl, 2-(N,N-diethylamino)ethyl, 2-(N,N-diisopropylamino)ethyl, 3-(N,N-dimethylamino)propyl, 3-(N,N-diethylamino)propyl, 3-
  • a saturated 3- to 8-membered heteromonocyclic group containing 1 to 2 nitrogen atoms group for example, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl morpholinyl, thiomorpholinyl groups (preferably a saturated 5- to 6-membered heteromonocyclic group containing 1 to 2 nitrogen atoms group such as pyrrolidinyl, imidazolidinyl, piperidinyl, piperidino, pyrazolidinyl and piperazinyl) can be mentioned.
  • Examples of an alkylene group which may be substituted with a hydroxy group include a linear or branched alkylene group (wherein the alkylene group may contain one oxygen atom) having 1 to 12 (preferably 1 to 6) carbon atoms such as methylene, ethylene, trimethylene, 2-methyltrimethylene, 2-hydroxytrimethylene, 3-hydroxytetramethylene, 3-methyltetramethylene, 2,2-dimethyltrimethylene, 1-methyltrimethylene, methylmethylene, ethylmethylene, tetramethylene, pentamethylene, hexamethylene, 2-ethoxyethylene (—CH 2 CH 2 OCH 2 CH 2 —), methoxymethylene (—CH 2 OCH 2 —), 1-ethoxyethylene (—CH 2 CH 2 OCH(CH 3 )—), 2-methoxyethylene (—CH 2 OCH 2 CH 2 —), 2-propoxyethylene (—CH 2 CH 2 CH 2 OCH 2 CH 2 —), 3-isoprop
  • Examples of a lower alkenylene group include a linear or branched alkenylene group having 1 to 3 double bonds and 2 to 6 carbon atoms such as vinylene, 1-propenylene, 1-methyl-1-propenylene, 2-methyl-1-propenylene, 2-propenylene, 2-butenylene, 1-butenylene, 3-butenylene, 2-pentenylene, 1-pentenylene, 3-pentenylene, 4-pentenylene, 1,3-butadienylene, 1,3-pentadienylene, 2-pentene-4-ylene, 2-hexenylene, 1-hexenylene, 5-hexenylene, 3-hexenylene, 4-hexenylene, 3,3-dimethyl-1-propenylene, 2-ethyl-1-propenylene, 1,3,5-hexatrienylene, 1,3-hexadienylene, 1,4-hexadienylene groups.
  • vinylene 1-propenylene, 1-methyl-1-
  • Examples of a lower alkylene group include a linear or branched alkenylene group having 1 to 6 carbon atoms such as methylene, ethylene, trimethylene, 2-methyltrimethylene, 3-methyltetramethylene, 2,2-dimethyltrimethylene, 1-methyltrimethylene, methylmethylene, ethylmethylene, tetramethylene, pentamethylene and hexamethylene groups.
  • the heterocyclic compound represented by the above-described general formula (1) can be produced in various kinds of methods, but, for example, it can be produced by a method shown in the following reaction formula.
  • ring Q, A and R 2 are the same as defined above, and X 1 represents a halogen atom or a group which causes a substitution reaction the same as in a halogen atom).
  • examples of a group which causes a substitution reaction the same as in a halogen atom include a lower alkanesulfonyloxy group, an arylsulfonyloxy group and an aralkylsulfonyloxy group.
  • a halogen atom shown as X 1 in the general formula (2) is the same as defined above.
  • examples include a linear or branched alkanesulfonyloxy group having 1 to 6 carbon atoms such as methanesulfonyloxy, ethanesulfonyloxy, n-propanesulfonyloxy, isopropanesulfonyloxy, n-butanesulfonyloxy, tert-butanesulfonyloxy, n-pentanesulfonyloxy and n-hexanesulfonyloxy groups.
  • a linear or branched alkanesulfonyloxy group having 1 to 6 carbon atoms such as methanesulfonyloxy, ethanesulfonyloxy, n-propanesulfonyloxy, isopropanesulfonyloxy, n-butanesulfonyloxy, tert-butanesulfonyloxy, n-pentanesulfonyloxy and
  • examples include phenylsulfonyloxy and naphthylsulfonyloxy groups which may have 1 to 3 substituents selected from the group consisting of a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkoxy group having 1 to 6 carbon atoms, a nitro group and a halogen atom on the phenyl ring, for example.
  • a phenylsulfonyloxy group which may have a substituent include phenylsulfonyloxy, 4-methylphenylsulfonyloxy, 2-methylphenylsulfonyloxy, 4-nitrophenylsulphonyloxy, 4-methoxyphenylsulfonyloxy, 2-nitrophenylsulphonyloxy, 3-chlorophenylsulphonyloxy groups.
  • a naphthylsulfonyloxy group include ⁇ -naphthyl sulfonyloxy, ⁇ -naphthyl sulfonyloxy groups.
  • examples include a linear or branched alkanesulfonyloxy group having 1 to 6 carbon atoms and substituted with a phenyl group, a linear or branched alkanesulfonyloxy group having 1 to 6 carbon atoms and substituted with a naphthyl group, which groups which may have 1 to 3 substituents selected from the group consisting of a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkoxy group having 1 to 6 carbon atoms, a nitro group and a halogen atom on the phenyl ring, for example.
  • a phenylsulfonyloxy group substituted with a naphthyl group include benzylsulfonyloxy, 2-phenylethylsulfonyloxy, 4-phenylbutylsulfonyloxy, 4-methylbenzylsulfonyloxy, 2-methylbenzylsulfonyloxy, 4-nitrobenzylsulfonyloxy, 4-methoxybenzylsulfonyloxy, 3-chlorobenzylsulfonyloxy groups.
  • alkanesulfonyloxy group substituted with a naphthyl group include ⁇ -naphthylmethyl sulfonyloxy, ⁇ -naphthylmethyl sulfonyloxy groups.
  • reaction of a compound represented by the general formula (2) and a compound represented by the general formula (3) is performed without solvent or in an inert solvent in the absence or presence of a basic compound.
  • an inert solvent examples include water; ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether, ethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene, xylene; lower alcohols such as methanol, ethanol, isopropanol; ketones such as acetone, methyl ethyl ketone; polar solvents such as N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), hexamethylphosphoric triamide, acetonitrile.
  • ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether, ethylene glycol dimethyl ether
  • aromatic hydrocarbons such as benzene, toluene, xylene
  • lower alcohols such as methanol, ethanol, isopropanol
  • ketones such
  • alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, cesium hydroxide, lithium hydroxide
  • alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, lithium carbonate
  • alkaline metal hydrogen carbonates such as lithium hydrogen carbonate, sodium hydrogen carbonate, potassium bicarbonate
  • alkaline metals such as sodium, potassium
  • inorganic bases such as sodium amide, sodium hydride, potassium hydride and alkaline metal alcoholates
  • organic bases such as triethylamine, tripropylamine, pyridine, quinoline, piperidine, imidazole, N-ethyldiisopropylamine, dimethylaminopyridine, trimethylamine, dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo[4.3.0]nonene-5 (DBN), 1,
  • the amount to be used of a basic compound is usually 0.5 to 10 times, preferably 0.5 to 6 times molar amount of a compound of the general formula (2).
  • reaction can be performed with addition of an alkaline metal iodide such as potassium iodide, sodium iodide as a reaction accelerator, if necessary.
  • an alkaline metal iodide such as potassium iodide, sodium iodide as a reaction accelerator, if necessary.
  • the ratio to be used of a compound of the general formula (2) and a compound of the general formula (3) in the above-mentioned reaction Formula 1 may be usually at least 0.5 times, preferably, 0.5 to 5 times molar amount of the former.
  • the above-described reaction is performed usually from room temperature to 200° C., preferably from room temperature to 150° C. and generally completed in about 1 to 30 hours.
  • X 2 represents a hydroxy group, a halogen atom or a group which causes a substitution reaction similar to a halogen atom).
  • reaction of a compound represented by the general formula (4) and a compound represented by the general formula (5a) is performed under similar reaction condition as in the reaction of a compound represented by the general formula (2) and a compound represented by the general formula (3) in the above-mentioned Reaction Formula 1.
  • reaction of a compound (4) and a compound (5a) can be performed in an appropriate solvent in the presence of a condensing agent.
  • halogenated hydrocarbons such as chloroform, dichloromethane, dichloroethane, carbon tetrachloride; aromatic hydrocarbons such as benzene, toluene, xylene; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dimethoxyethane; esters such as methyl acetate, ethyl acetate, isopropyl acetate; polar solvent such as acetonitrile, pyridine, acetone, DMF, DMSO, hexamethylphosphoric triamide or a mixed solvent of these.
  • polar solvent such as acetonitrile, pyridine, acetone, DMF, DMSO, hexamethylphosphoric triamide or a mixed solvent of these.
  • azocarboxylates such as diethyl azodicarboxylate and a mixture of phosphorus compounds such as triphenylphosphine can be mentioned.
  • the amount of a condensing agent to be used is usually at least equimolar, preferably equimolar to 2 times the amount of compound (4).
  • the amount of compound (5a) to be used is usually at least equimolar, preferably equimolar to 2 times the amount of compound (4).
  • This reaction precedes usually 0 to 200° C., preferably 0 to 150° C. and generally completed in about 1 to 10 hours.
  • R 2 is the same as above, X 3 represents a halogen atom or a group which causes a substitution reaction similar to a halogen atom, A 2 represents a lower alkylene group, and
  • the ring Q1 represents a bicyclic group selected from the group consisting of:
  • the ring Q1 may have at least one substituent selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a hydroxy group, a lower alkoxy group, an aryl group, an aryl lower alkyl group, an aryl lower alkoxy group, a lower alkenyloxy group, a lower alkanoyl group, a lower alkanoyloxy group, a cycloalkyl group, a cycloalkyl (lower) alkyl group, a halogen atom, a carbamoyl group which may have a lower alkyl group, a carboxy group, a lower alkoxycarbonyl group, an amino group which may have a lower alkanoyl group, a nitro group, a hydroxy lower alkyl group, an amino lower alkyl group which may have a lower alkyl group, a thienyl group, a saturated 3- to 8-
  • reaction of a compound represented by the general formula (6) and a compound represented by the general formula (5b) is performed under similar reaction condition as in the reaction of a compound represented by the general formula (2) and a compound represented by the general formula (3) in the above-mentioned Reaction Formula 1.
  • the compound represented by the general formula (2) which is used as a starting material, can be produced, for example, according to the following reaction Formula 4 and the compound represented by the general formula (5) can be produced, for example, according to the Reaction Formula 5 below respectively.
  • reaction of a compound represented by the general formula (4) and a compound represented by the general formula (8) is performed under similar reaction condition as in the reaction of a compound represented by the general formula (4) and a compound represented by the general formula (5a) in the above-mentioned Reaction Formula 2.
  • R 2 , A and X 2 are the same as above, and X 4 represents a halogen atom or a group which causes a substitution reaction the same as in a halogen atom).
  • reaction of a compound represented by the general formula (3) and a compound represented by the general formula (9) is performed under similar reaction condition as in the reaction of a compound represented by the general formula (2) and a compound represented by the general formula (3) in the above-mentioned Reaction Formula 1.
  • Both the compound of the general formula (3) and the compound of the general formula (9) are well-known compounds readily available.
  • a compound having a hydroxy group at ring Q can be produced by treating a compound having a methoxy group at ring Q in compound (1) in the presence of an acid in an appropriate solvent or without solvent.
  • examples include water; aromatic hydrocarbons such as benzene, toluene, xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglyme, diglyme; halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride; lower alcohols such as methanol, ethanol, isopropanol, butanol, tert-butanol, ethylene glycol; fatty acids such as acetic acid; esters such as ethyl acetate, methyl acetate; ketones such as acetone, methyl ethyl ketone; acetonitrile, pyridine, DMF, DMSO, hexamethylphosphoric triamide or a mixed solvent of these.
  • aromatic hydrocarbons such as benzene, toluene, xylene
  • ethers such as diethyl ether
  • examples include mineral acids such as hydrobromic acid, hydrochloric acid, concentrated sulfuric acid; fatty acids such as formic acid, acetic acid, organic acids such as p-toluenesulfonic acid; Lewis acids such as aluminum chloride, zinc chloride, iron chloride, tin chloride, boron trifluoride, boron tribromide; iodides such as sodium iodide, potassium iodides; a mixture of a Lewis acid and an iodide as mentioned above.
  • mineral acids such as hydrobromic acid, hydrochloric acid, concentrated sulfuric acid
  • fatty acids such as formic acid, acetic acid, organic acids such as p-toluenesulfonic acid
  • Lewis acids such as aluminum chloride, zinc chloride, iron chloride, tin chloride, boron trifluoride, boron tribromide
  • iodides such as sodium iodide, potassium iodides
  • Such an acid is usually used at 0.1 to 15 times, preferably 0.5 to 10 times molar amount of compound (1).
  • the acid is usually used in a large excess amount.
  • This reaction is performed usually 0 to 150° C., preferably at around 0 to 100° C., and generally completed for about 0.5 to 75 hours.
  • the starting compounds used in each of the above reaction formula may be suitable salt, the object compound obtained by each of the reaction may form a suitable salt.
  • suitable salts include the preferable salts of compound (1) exemplified below.
  • the preferable salts of compound (1) are pharmacologically acceptable salts and examples include metal salts such as alkali metal salts (for example, sodium salt potassium salt, etc.), alkaline earth metal salts (for example, calcium salt, magnesium salt, etc.), salts of inorganic bases such as ammonium salt, alkaline metal carbonates (for example, lithium carbonate, potassium carbonate, sodium carbonate, cesium carbonate, etc.), alkaline metal hydrogen carbonates (for example, lithium hydrogen carbonate, sodium hydrogen carbonate, potassium bicarbonate, etc.), alkali metal hydroxides (for example, lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, etc.); for example, salts of organic bases such as tri(lower)alkylamine (for example, trimethylamine, triethylamine, N-ethyldiisopropylamine), pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline,
  • solvate for example, hydrate, ethanolate, etc.
  • Each of the object compounds obtained by each of the general formulas can be isolated and purified from the reaction mixture by, for example, subjecting the reaction mixture to isolation operation such as filtration, concentration and extraction after cooling to separate a crude reaction product followed by conventional purification operation such as column chromatography or recrystallization.
  • the compound represented by the general formula (1) of the present invention naturally encompasses isomers such as geometrical isomer, stereoisomer and enantiomer.
  • the compound of the general formula (1) and a salt thereof can be used in a common form of pharmaceutical preparation.
  • the pharmaceutical preparation is prepared by using usually used diluent or excipient such as filler, extending agent, binder, humectant, disintegrating agent, surfactant and lubricant.
  • diluent or excipient such as filler, extending agent, binder, humectant, disintegrating agent, surfactant and lubricant.
  • various forms can be selected depending on the purpose of treatment, and typical examples include a tablet, pill, powder, solution, suspension, emulsion, granule, capsule, suppository, and injection (solution, suspension).
  • excipient such as lactose, saccharose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicate
  • binder such as water, ethanol, propanol, simple syrup, glucose solution, starch liquid, gelatine solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone
  • disintegrating agent such as dried starch, sodium alginate, agar powder, laminaran powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose
  • disintegration preventing agent such as saccharose, stearin, cacao butter, hydrogenated oil
  • sorbefacient such as quaternary ammonium base, sodium lauryl sulfate
  • moisturizing such as lactose, saccharose, saccharose, sodium chloride,
  • excipient such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, kaolin, talc; binder such as powdered gum arabic, powdered tragacanth, gelatine, ethanol; disintegrating agent such as laminaran, agar can be used, for example.
  • various materials conventionally well known as carrier can be widely used.
  • examples thereof include polyethylene glycol, cacao butter, higher alcohol, esters of higher alcohol, gelatine, semisynthesized glyceride, for example.
  • a capsule is usually prepared according to a conventional method by mixing active ingredient compounds with various carrier exemplified above and filling them into a hard gelatin capsule, a soft capsule or the like.
  • solution, emulsion and suspension are sterilized and isotonic to the blood and for forming in these modes
  • any of those conventionally used in the art as diluent can be used, and, for example, water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid ester, etc. can be used.
  • the pharmaceutical preparation may contain common salt, glucose or glycerine in an amount sufficient to prepare an isotonic solution in this case, and conventional solubilizer, buffer, soothing agent may be also added. Pigment, preservative, aromatic, flavor, sweetening and other pharmaceuticals may be further contained as required.
  • the amount of a compound of the general formula (1) or a salt thereof to be contained in the pharmaceutical preparation of the present invention is not particularly limited but usually about 1 to 70% by weight in the preparation composition is suitable and preferably about 1 to 30% by weight.
  • the pharmaceutical preparation of the present invention may be administered by a method in accordance with specific form of the preparation, age, sex and the other conditions of a patient, severity of disease, etc.
  • a method in accordance with specific form of the preparation for example, in the case of tablet, pill, solution, suspension, emulsion, granule and capsule, it is orally administered.
  • it is intravenously administered alone or in a mixture with conventional replacement fluid such as glucose and amino acids, and if necessary, and the preparation alone may be also administered intramuscularly, intracutaneously, subcutaneously or interperitoneally. It is administered in rectum in the case of suppository.
  • Applied dose of the pharmaceutical preparation of the present invention is appropriately selected in accordance with dosage regimen, age, sex and the other conditions of a patient, severity of disease, etc., but it is suitable that the amount of the active ingredient compound is usually about 0.1 to 10 mg per 1 kg of body weight per day. In addition, it is desirable that the active ingredient compound is contained in the preparation of a dosage unit form in the range of about 1 to 200 mg.
  • the compound of the present invention has D 2 receptor partial agonist effect, 5-HT 2A receptor antagonist effect and serotonin uptake inhibitory effect (or serotonin uptake inhibitory effect).
  • the D 2 receptor partial agonist effect suppresses dopaminergic (DA) neurotransmission when it is enhanced, and accelerates the DA neurotransmission when it is lowered and thus has a function to stabilize the DA neurotransmission to a normal state (dopamine system stabilizer).
  • DA dopaminergic
  • lowering excellent clinically improving effect on the conditions based on the DA abnormal neurotransmission (enhancement and lowering), for example, improving effect on positive and negative symptoms, improving effect on cognitive impairment, improving effect on depressive symptom, etc. are developed without developing side effects (See Michio Toru: Seishin-Igaku (Psychiatry), Vol. 46, pp.
  • 5-HT 2A receptor antagonist effect reduces extrapyramidal side effects, develops superior clinical effects, and is effective for improvement of negative symptoms, improvement of cognitive impairment, improvement of depression condition, improvement of insomnia, for example (See Jun Ishigooka and Ken Inada: Rinsho-Seishin-Yakuri (Japanese Journal of Clinical Psychopharmacology), Vol. 4, pp. 1653-1664 (2001), Mitsukuni Murasaki Rinsho-Seishin-Yakuri (Japanese Journal of Clinical Psychopharmacology), Vol. 1, pp. 5-22 (1998), Puller, I. A. et al., Eur. J. Pharmacol., 407:39-46, 2000, and Meltzer, H. Y. et al, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27: 1159-1172, 2003).
  • Serotonin uptake inhibitory effect is effective for improving depressive symptoms, for example (See Mitsukuni Murasaki: Rinsho-Seishin-Yakuri (Japanese Journal of Clinical Psychopharmacology), Vol. 1, pp. 5-22 (1998)).
  • the compounds of the present invention are excellent in all of these three effects, or remarkably excellent in one or two of these effects.
  • ⁇ 1 receptor antagonist effect is effective for improving positive symptoms of schizophrenia (See Svensson, T. H.: Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27: 1145-1158, 2003).
  • the compounds of the present invention have a wide treatment spectrum for and excellent clinical effect on schizophrenia and other central nervous system disorders.
  • the compounds of the present invention are extremely effective for the treatment or prevention of central nervous system disorders including the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar disorder (for example, bipolar I type disorder and bipolar II type disorder); depression; endogenous depression; major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; anxiety disorder (for example, panic attack, panic disorder, agoraphobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, acute stress disorder, etc.); somatoform disorder (for example, hysteria, somatization disorder, conversion disorder, pain disorder, hypochondriasis, etc.); factitious disorder; dissociative disorder; sexual disorder (for example, sexual dysfunction, sexual desire disorder, sexual arousal disorder, erectile dysfunction, etc.); eating disorder (for example, anorexia nervosa, bulimia,
  • the compounds of the present invention have little or no side effects and they are excellent in safety and tolerability.
  • Methanesulfonyl chloride (1.0 ml) was added to a dichloromethane (80 ml) solution of 2.8 g of 7-(4-hydroxy-3-methyl butoxy)-3,4-dihydro-1H-quinolin-2-one and 2.4 ml of triethylamine while being stirred under ice-cooling and stirred at room temperature overnight. Water was added to the reaction solution, which was then extracted with dichloromethane and, after washed with water, dried over magnesium sulfate, and the solvent was evaporated under reduced pressure.
  • 6-(3-chloropropoxy)-2H-isoquinolin-1-one in the form of a pale yellow powder was prepared from 6-hydroxy-2H-isoquinolin-1-one using 1-bromo-3-chloropropane.
  • tert-butyl 4-benzo[b]thiophen-4-yl-3-methylpiperazin-1-carboxylate was prepared from tert-butyl 3-methylpiperazin-1-carboxylate and 4-bromobenzo[b]thiophene.
  • Lithium aluminum hydride (1.18 g, 24.8 mmol) was added to a solution of 5.26 g (16.5 mmol) of ethyl 3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propionate in tetrahydrofuran (55 ml) with cooling in an ice-bath, followed by stirring at room temperature for 4 hours.
  • Potassium carbonate (3.87 g, 28 mmol) was added to a solution of 7.76 g (23.3 mmol) of butyl 4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)acetate in 90% methanol (150 ml) followed by stirring at room temperature for 2 hours. Water was added thereto and the reaction mixture was extracted with methylene chloride. The organic phase was dried over magnesium sulfate and concentrated under reduced pressure.
  • 1-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-1H-quinolin-2-one was prepared from 1-(4-chlorobutyl)-1H-quinolin-2-one, and after it was made into an ethanol solution, 1N hydrochloric acid ethanol solution was added thereto, precipitated crystals were separated by filtration, and thereby 1-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl]-1H-quinolin-2-one hydrochloride was obtained in the form of a white powder.
  • 1-[5-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)pentyl]-1H-quinolin-2-one was prepared from 1-(5-chloropentyl)-1H-quinolin-2-one, and after it was made into an ethanol solution, 1N hydrochloric acid ethanol solution was added thereto, precipitated crystals were separated by filtration, and thereby 1-[5-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)pentyl]-1H-quinolin-2-one hydrochloride was obtained in the form of a white powder.
  • 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one was prepared from 6-(3-chloropropoxy)-3,4-dihydro-1H-quinolin-2-one, and after it was made into a methanol solution, 0.5N hydrochloric acid methanol solution was added thereto, precipitated crystals were separated by filtration, recrystallized from a mixed solvent of ethyl acetate-diethyl ether and thereby 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one hydrochloride was obtained in the form of a white powder.
  • 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydro-2H-isoquinolin-1-one was prepared from 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoquinolin-1-one using methyl iodide.
  • 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-ethyl-3,4-dihydro-2H-isoquinolin-1-one was prepared from 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-isoquinolin-1-one using ethyl iodide.
  • 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-2H-isoquinolin-1-one was prepared from 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2H-isoquinolin-1-one using methyl iodide, and after it was made into an ethyl acetate solution, 1N hydrochloric acid ethanol solution was added thereto, precipitated crystals were separated by filtration, recrystallized from ethyl acetate and thereby 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-2H-isoquinolin-1-one hydrochloride was obtained in the form of a white powder.
  • Fumaric acid was added to a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one in methanol and dichloromethane and the solvent was evaporated under reduced pressure. The residue was recrystallized from ethanol and thereby 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one fumarate was obtained in the form of a white powder.
  • Citric acid was added to a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one in methanol and dichloromethane and the solvent was evaporated under reduced pressure. The residue was recrystallized from 50% ethanol and thereby 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one citrate was obtained in the form of a white powder.
  • Fumaric acid was added to an ethanol solution of 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydro-2H-isoquinolin-1-one and the solvent was evaporated under reduced pressure. The residue was recrystallized from 70% ethanol and thereby 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydro-2H-isoquinolin-1-one fumarate was obtained in the form of a pale yellow powder.
  • Fumaric acid was added to an ethanol solution of 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydro-2H-isoquinolin-1-one and the solvent was evaporated under reduced pressure. The residue was recrystallized from 90% ethanol and thereby 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydro-2H-isoquinolin-1-one difumarate was obtained in the form of white prism crystal.
  • Methanesulfonic acid was added to an ethanol solution of 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydro-2H-isoquinolin-1-one and the solvent was evaporated under reduced pressure. The residue was recrystallized from 80% ethanol and thereby 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2-methyl-3,4-dihydro-2H-isoquinolin-1-one methanesulfonate was obtained in the form of pale yellow prism crystal.
  • PS-triphenylphosphine 110 mg, 3 mmol/g
  • dibenzyl azodicarboxylate 70 mg, 0.3 mmol
  • 7-hydroxy-6-methoxy-3,4-dihydroisoquinoline 80 mg, 0.45 mmol
  • 3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propan-1-ol 83 mg, 0.3 mmol
  • the reaction mixture was cooled to room temperature and insoluble matters were removed by filtration. The filtrate was concentrated under reduced pressure.
  • Acetic anhydride (0.34 ml, 3.6 mmol) and pyridine (0.34 ml, 4.3 mmol) were added to a solution of 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1,2,3,4-tetrahydroquinoline (0.49 g, 1.2 mmol) in methylene chloride (10 ml) with cooling in an ice-bath, followed by stirring at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and water and ethyl acetate were added to the residue to separate the organic phase from the water phase.
  • Lithium aluminum hydride 160 mg, 4.2 mmol was added to a solution of 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one (1.6 g, 3.8 mmol) in tetrahydrofuran (40 ml), followed by stirring under reflux for 1 hour.
  • the reaction mixture was cooled in an ice-bath, and water (0.16 ml), 15% sodium hydroxide aqueous solution (0.16 ml) and water (0.5 ml) were added thereto in this order. After stirring the mixture, insoluble matters were removed by filtration and the filtrate was concentrated under reduced pressure.
  • Triethylamine (0.25 ml, 1.8 mmol) and isobutyl chloroformate (0.19 ml, 1.4 mmol) were added to a solution (10 ml) of 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]quinolin-2-carboxylic acid (0.53 g, 1.2 mmol) in acetonitrile with cooling in an ice-bath, followed by stirring at 0° C. for 3 hours. 28% Aqueous ammonia (0.15 ml) was added thereto and the reaction mixture was stirred at room temperature for 5 minutes.
  • Example 64 to 196 shown in the following Tables 1 to 21 can be prepared in the same manner as in Example 1, using corresponding starting materials.
  • the assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem. Pharmacol., 1985; 34: 2251-2259).
  • Wistar male rats were decapitated, the brain was retrieved immediately and corpus striatum was taken out. It was homogenized in 50 mM tris(hydroxymethyl)aminomethane (Tris)-hydrochloric acid buffer (pH 7.4) of a volume 50 times of the weight of the tissue using a homogenizer with a high-speed rotating blade, and centrifuged at 4° C., 48,000 ⁇ g for 10 minutes. The obtained precipitate was suspended again in the above-described buffer of a volume 50 times of the weight of the tissue and after incubated at 37° C. for 10 minutes, centrifuged in the above-described condition.
  • Tris tris(hydroxymethyl)aminomethane
  • the obtained precipitate was suspended in 50 mM (Tris)-hydrochloric acid buffer (containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , pH 7.4) of a volume 25 times of the weight of the tissue and preserved by freezing at ⁇ 85° C. till it was used for binding assay as a membrane specimen.
  • 50 mM (Tris)-hydrochloric acid buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , pH 7.4
  • the binding assay was performed using 40 ⁇ l of the membrane specimen, 20 ⁇ l of [ 3 H]-raclopride (final concentration 1 to 2 nM), 20 ⁇ l of a test drug and 50 mM Tris-hydrochloric acid buffer (containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , pH 7.4) so that the total amount was 200 ⁇ l (final dimethylsulfoxide concentration 1%).
  • the reaction was performed at room temperature for 1 hour and terminated by conducting suction filtration with a cell harvester on a glass fiber filter plate.
  • the filter plate made of glass fiber was washed with 50 mM Tris-hydrochloric acid buffer (pH 7.4), and after dried, a microplate liquid scintillation cocktail was added and the radioactivity was measured with a microplate scintillation counter. Radioactivity in the presence of 10 ⁇ M (+)-butaclamol hydrochloride was assumed as nonspecific binding.
  • IC 50 value was calculated from concentration-dependent reaction using a non-linear analysis program. Ki value was calculated from IC 50 value using Cheng-Prussoff formula. The results are shown in the following Table 22.
  • Wistar male rats were decapitated, the brain was retrieved immediately and frontal cortex was taken out. It was homogenized in 0.25 M sucrose of a volume 10 times of the weight of the tissue using a Teflon glass homogenizer, and centrifuged at 4° C., 1,000 ⁇ g for 10 minutes. The obtained supernatant was transferred to another centrifuge tube and suspended in 0.25 M sucrose of a volume 5 times of the weight of the tissue and the precipitate was centrifuged in the above-described condition.
  • the obtained supernatant was combined with the supernatant obtained above and adjusted to a volume 40 times of the weight of the tissue with 50 mM Tris-hydrochloric acid buffer (pH 7.4), and centrifuged at 4° C., 35,000 ⁇ g for 10 minutes.
  • the obtained precipitate was suspended again in the above-described buffer of a volume 40 times of the weight of the tissue and centrifuged in the above-described condition.
  • the obtained precipitate was suspended in the above-described buffer of a volume 20 times of the weight of the tissue and preserved by freezing at ⁇ 85° C. till it was used for binding assay as a membrane specimen.
  • the binding assay was performed using 40 ⁇ l of the membrane specimen, 20 ⁇ l of [ 3 H]-Ketanserin (final concentration 1 to 3 nM), 20 ⁇ l of a test drug and 50 mM Tris-hydrochloric acid buffer (pH 7.4) so that the total amount was 200 ⁇ l (final dimethylsulfoxide concentration 1%).
  • the reaction was performed at 37° C. for 20 minutes and terminated by conducting suction filtration with a cell harvester on a glass fiber filter plate.
  • the filter plate made of glass fiber was washed with 50 mM Tris-hydrochloric acid buffer (pH 7.4), and after dried, a microplate liquid scintillation cocktail was added and the radioactivity was measured with a microplate scintillation counter. Radioactivity in the presence of 10 ⁇ M spiperone was assumed as nonspecific binding.
  • IC 50 value was calculated from concentration-dependent reaction using a non-linear analysis program. Ki value was calculated from IC 50 value using Cheng-Prussoff formula. The results are shown in the following Table 23.
  • the assay was performed according to the method by Gro ⁇ G et al. (Gro ⁇ G, Hanft G and Kolassa N. Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for ⁇ 1-adrenoceptor binding sites. Naunyn-Schmiedeberg's Arch Pharmacol., 1987, 336: 597-601).
  • Wistar male rats were decapitated, the brain was retrieved immediately and cerebral cortex was taken out. It was homogenized in 50 mM Tris-hydrochloric acid buffer (100 mM NaCl, containing 2 mM dihydrogen disodium ethylene diamine tetraacetate, pH 7.4) of a volume 20 times of the weight of the tissue using a homogenizer with a high-speed rotating blade, and centrifuged at 4° C., 80,000 ⁇ g for 20 minutes. The obtained precipitate was suspended in the above-described buffer of a volume 20 times of the weight of the tissue and after incubated at 37° C. for 10 minutes, centrifuged in the above-described condition.
  • Tris-hydrochloric acid buffer 100 mM NaCl, containing 2 mM dihydrogen disodium ethylene diamine tetraacetate, pH 7.4
  • the obtained precipitate was suspended again in the above-described buffer of a volume 20 times of the weight of the tissue and centrifuged in the above-described condition.
  • the obtained precipitate was suspended in 50 mM (Tris)-hydrochloric acid buffer (containing 1 mM dihydrogen disodium ethylene diamine tetraacetate, pH 7.4) of a volume 20 times of the weight of the tissue and preserved by freezing at ⁇ 85° C. till it was used for binding assay as membrane specimen.
  • the binding assay was performed using 40 ⁇ l of the membrane specimen, 20 ⁇ l of [ 3 H]-prazosin (final concentration 0.2 to 0.5 nM), 20 ⁇ l of a test drug and 50 mM Tris-hydrochloric acid buffer (containing 1 mM EDTA, pH 7.4) so that the total amount was 200 ⁇ l (final dimethylsulfoxide concentration 1%).
  • the reaction was performed at 30° C. for 45 minutes and terminated by conducting suction filtration with a cell harvester on a glass fiber filter plate.
  • the filter plate made of glass fiber was washed with 50 mM Tris-hydrochloric acid buffer (pH 7.4), and after dried, a microplate liquid scintillation cocktail was added and the radioactivity was measured with a microplate scintillation counter. Radioactivity in the presence of 10 ⁇ M phentolamine hydrochloride was assumed as nonspecific binding.
  • IC 50 value was calculated from concentration-dependent reaction using a non-linear analysis program. Ki value was calculated from IC 50 value using Cheng-Prussoff formula.
  • Partial agonistic activity on dopamine D 2 receptor was evaluated by quantitatively determining cyclic AMP production inhibitory effect of a test compound in dopamine D 2 receptor expression cells in which adenosine 3′,5′-cyclic monophosphate (cyclic AMP) production was induced by forskolin stimulation.
  • cyclic AMP adenosine 3′,5′-cyclic monophosphate
  • CMOS cells Human recombinant dopamine D 2 receptor expressing Chinese hamster ovary/DHFR( ⁇ ) cells were cultured in a culture medium (Iscove's Modified Dulbecco's Medium (IMDM culture medium), 10% fetal bovine serum, 50 I.U./ml penicillin, 50 ⁇ g/ml streptomycin, 200 ⁇ g/ml geneticin, 0.1 mM sodium hypoxanthine, 16 ⁇ M thymidine) at 37° C. and 5% carbon dioxide condition. Cells were seeded at 10 4 cells/well on a 96-well microtiter plate coated with poly-L-lysine and grown under the same condition for 2 days.
  • IMDM culture medium Iscove's Modified Dulbecco's Medium
  • fetal bovine serum 50 I.U./ml
  • penicillin 50 ⁇ g/ml streptomycin
  • 200 ⁇ g/ml geneticin 200 ⁇ g/ml geneticin
  • IMDM culture medium 0.1 mM sodium hypoxanthine, 16 ⁇ M thymidine
  • the culture medium was replaced with 50 ⁇ l of culture medium (IMDM culture medium, 0.1% sodium ascorbate, 0.1 mM sodium hypoxanthine, 16 ⁇ M thymidine) having dissolved therein 3 ⁇ M of a test compound.
  • the culture medium was replaced with 100 ⁇ l of forskolin stimulative culture medium (IMDM culture medium, 0.1% sodium ascorbate, 0.1 mM sodium hypoxanthine, 16 ⁇ M thymidine, 10 ⁇ M forskolin, 500 ⁇ M 3-isobutyl-1-methylxanthine) having 3 ⁇ M of the test compound dissolved therein and allowed to incubate at 37° C., 5% carbon dioxide condition for 10 minutes.
  • forskolin stimulative culture medium IMDM culture medium, 0.1% sodium ascorbate, 0.1 mM sodium hypoxanthine, 16 ⁇ M thymidine, 10 ⁇ M forskolin, 500 ⁇ M 3-isobutyl-1-methylxanthine
  • Lysis 1B aqueous solution (Amersham Bioscience, reagent attached to cyclic AMP biotrack enzyme immunoassay system) was dispensed and shaken for 10 minutes. The aqueous solution of each well was used as a sample for measurement. Samples for measurement quadruply diluted were subjected to measurement of the quantity of cyclic AMP using the above-described enzyme immunoassay system. Inhibition ratio of the respective test compound was calculated assuming that the quantity of cyclic AMP of the well to which no test compound was added was 100%. In this empiric test system, dopamine which was used as a control drug suppressed the quantity of cyclic AMP to about 10% as the maximum activity.
  • test compounds had partial agonistic activity for dopamine D 2 receptor in the above-described test.
  • test compounds Since the test compounds has partial agonistic activity for dopamine D 2 receptor, they can stabilize dopamine neurotransmission to a normal condition in a schizophrenia patient and as a result, exhibit, for example, positive and negative condition improving effect, cognitive impairment improving effect and the other symptom improving effects without causing side effects.
  • Wistar rats male, six-seven weeks old, Japan SLC, Inc. were used as test animals.
  • a test compound was suspended in 5% gum arabic/(physiological saline or water) using an agate mortar and was diluted with the same solvent if necessary.
  • the stereotyped behavior of each animal was quantified according to the following condition and score made at three points were summed up and the anti-apomorphine effect was evaluated. Six test animals were used for each group.
  • Non-clinical statistical analysis system was used for all statistical processing. When the significance probability value was lower than 0.05, it was judged that a significant difference existed. The difference of the score between the solvent administration group and each test compound administration group was analyzed using Wilcoxon rank-sum test or Steel test. In addition, linear regression analysis was used for calculating 50% effective dose (95% confidence interval).
  • test compounds showed inhibitory effect for apomorphine-induced stereotyped behavior, it was confirmed that the test compounds have D 2 receptor antagonistic effect.
  • Wistar rats male, six-seven weeks old, Japan SLC, Inc. were used as test animals.
  • a test compound was suspended in 5% gum arabic/(physiological saline or water) using an agate mortar and was diluted with the same solvent if necessary.
  • Test animals were fasted overnight from the day before. DOI (5.0 mg/kg) was subcutaneously administered (1 ml/kg) 1 hour after each test compound was orally administered (5 ml/kg). The number of head twitches was counted for 10 minutes immediately after DOI injection. Six test animals were used for each group.
  • Non-clinical statistical analysis was used for all statistical processing. When the significance probability value was lower than 0.05, it was judged that a significant difference existed. The difference of the number of head twitches between the solvent administration group and each test compound administration group was analyzed using t-test or Dunnett's test. In addition, linear regression analysis was used for calculating 50% effective dose (95% confidence interval).
  • test compounds showed inhibitory effect for DOI-induced head twitch, it was confirmed that the test compounds have serotonin 5HT 2A receptor antagonistic effect.
  • Wistar rats male, six-seven weeks old, Japan SLC, Inc. were used as test animals.
  • a test compound was suspended in 5% gum arabic/(physiological saline or water) using an agate mortar and was diluted with the same solvent if necessary.
  • Test animals were fasted overnight from the day before observation on catalepsy and ptosis was performed 1, 2, 4, 6 and 8 hours after each test compound was orally administered (5 ml/kg). Six test animals were used for each group.
  • catalepsy induction effect of a test compound was dissociated from inhibitory effect on apomorphine-induced stereotyped behavior, therefore it was suggested that apprehension for extrapyramidal side effect in clinic would be low.
  • Wistar male rats were decapitated, the brain was retrieved and frontal cortex was dissected out, and it was homogenized in 0.32 M sucrose solution of a weight 20 times of the weight of the tissue using a Potter type homogenizer.
  • the homogenate was centrifuged at 4° C., 1,000 ⁇ g for 10 minutes, the obtained supernatant was further centrifuged at 4° C., 20,000 ⁇ g for 20 minutes, and the pellet was suspended in an incubation buffer (20 mM Hepes buffer (pH 7.4) containing 10 mM glucose, 145 mM sodium chloride, 4.5 mM potassium chloride, 1.2 mM magnesium chloride, 1.5 mM calcium chloride), which was used as crude synaptosome fraction.
  • 5-HT uptake reaction was performed in a volume of 200 ⁇ l using a 96-well round bottom plate and pargyline (final concentration 10 ⁇ M) and sodium ascorbate (final concentration 0.2 mg/ml) were contained in the incubation buffer upon reaction and used.
  • Incubation buffer total counting
  • non-labeled 5-HT final concentration 10 ⁇ M, non-specific counting
  • diluted test compound final concentration 300 nM
  • One-tenth quantity of the final volume of the synaptosome fraction was added and after preincubated at 37° C. for 10 minutes, tritium labeled 5-HT solution (final concentration 8 nM) was added and uptake reaction was started at 37° C.
  • the uptake time was 10 minutes and the reaction was terminated by vacuum filtration through a 96-well fiber glass filter paper plate, and after the filter paper was washed with cold normal saline, it was dried enough and Microscint0 (Perkin-Elmer) was added to the filter and remaining radioactivity on the filter was measured.
  • the obtained tablet was coated with a film using a film coating agent made up of 10 g of TC-5 (trade name, product of Shin-Etsu Chemical Co., Ltd., hydroxypropyl methylcellulose), 3 g of polyethylene glycol 6000, 40 g of castor oil and an appropriate amount of ethanol to produce a film coated tablet of the above composition.
  • a film coating agent made up of 10 g of TC-5 (trade name, product of Shin-Etsu Chemical Co., Ltd., hydroxypropyl methylcellulose), 3 g of polyethylene glycol 6000, 40 g of castor oil and an appropriate amount of ethanol to produce a film coated tablet of the above composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
US15/815,650 2005-04-14 2006-04-12 Piperazine-substituted benzothiophenes for treatment of mental disorders Active 2029-11-05 USRE48059E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/815,650 USRE48059E1 (en) 2005-04-14 2006-04-12 Piperazine-substituted benzothiophenes for treatment of mental disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2005116698 2005-04-14
JP2005-116698 2005-04-14
US15/815,650 USRE48059E1 (en) 2005-04-14 2006-04-12 Piperazine-substituted benzothiophenes for treatment of mental disorders
US11/659,005 US7888362B2 (en) 2005-04-14 2006-04-12 Piperazine-substituted benzothiophenes for treatment of mental disorders
PCT/JP2006/308162 WO2006112464A1 (en) 2005-04-14 2006-04-12 Piperazine-substituted benzothiophenes for treatment of mental disorders

Publications (1)

Publication Number Publication Date
USRE48059E1 true USRE48059E1 (en) 2020-06-23

Family

ID=36645750

Family Applications (14)

Application Number Title Priority Date Filing Date
US11/659,005 Ceased US7888362B2 (en) 2005-04-14 2006-04-12 Piperazine-substituted benzothiophenes for treatment of mental disorders
US15/815,650 Active 2029-11-05 USRE48059E1 (en) 2005-04-14 2006-04-12 Piperazine-substituted benzothiophenes for treatment of mental disorders
US12/970,690 Active US8349840B2 (en) 2005-04-14 2010-12-16 Piperazine-substituted benzothiophenes for treatment of mental disorders
US13/688,108 Active US8618109B2 (en) 2005-04-14 2012-11-28 Piperazine-substituted benzothiophenes for treatment of mental disorders
US14/089,504 Active US9206167B2 (en) 2005-04-14 2013-11-25 Piperazine-substituted benzothiophenes for treatment of mental disorders
US14/928,972 Active US9480686B2 (en) 2005-04-14 2015-10-30 Piperazine-substituted benzothiophenes for treatment of mental disorders
US15/267,025 Abandoned US20170000786A1 (en) 2005-04-14 2016-09-15 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US15/585,098 Abandoned US20170231983A1 (en) 2005-04-14 2017-05-02 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US15/697,196 Active US9839637B1 (en) 2005-04-14 2017-09-06 Piperazine-substituted benzothiophenes for treatment of mental disorders
US15/799,520 Abandoned US20180214444A1 (en) 2005-04-14 2017-10-31 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US16/228,284 Abandoned US20190117648A1 (en) 2005-04-14 2018-12-20 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US16/459,048 Abandoned US20190321359A1 (en) 2005-04-14 2019-07-01 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US16/848,467 Abandoned US20200237755A1 (en) 2005-04-14 2020-04-14 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US17/131,635 Abandoned US20210113556A1 (en) 2005-04-14 2020-12-22 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/659,005 Ceased US7888362B2 (en) 2005-04-14 2006-04-12 Piperazine-substituted benzothiophenes for treatment of mental disorders

Family Applications After (12)

Application Number Title Priority Date Filing Date
US12/970,690 Active US8349840B2 (en) 2005-04-14 2010-12-16 Piperazine-substituted benzothiophenes for treatment of mental disorders
US13/688,108 Active US8618109B2 (en) 2005-04-14 2012-11-28 Piperazine-substituted benzothiophenes for treatment of mental disorders
US14/089,504 Active US9206167B2 (en) 2005-04-14 2013-11-25 Piperazine-substituted benzothiophenes for treatment of mental disorders
US14/928,972 Active US9480686B2 (en) 2005-04-14 2015-10-30 Piperazine-substituted benzothiophenes for treatment of mental disorders
US15/267,025 Abandoned US20170000786A1 (en) 2005-04-14 2016-09-15 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US15/585,098 Abandoned US20170231983A1 (en) 2005-04-14 2017-05-02 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US15/697,196 Active US9839637B1 (en) 2005-04-14 2017-09-06 Piperazine-substituted benzothiophenes for treatment of mental disorders
US15/799,520 Abandoned US20180214444A1 (en) 2005-04-14 2017-10-31 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US16/228,284 Abandoned US20190117648A1 (en) 2005-04-14 2018-12-20 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US16/459,048 Abandoned US20190321359A1 (en) 2005-04-14 2019-07-01 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US16/848,467 Abandoned US20200237755A1 (en) 2005-04-14 2020-04-14 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US17/131,635 Abandoned US20210113556A1 (en) 2005-04-14 2020-12-22 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders

Country Status (27)

Country Link
US (14) US7888362B2 (ko)
EP (1) EP1869025B3 (ko)
KR (1) KR100937623B1 (ko)
CN (1) CN101155804B (ko)
AR (1) AR053577A1 (ko)
AT (1) ATE496911T3 (ko)
AU (1) AU2006237905C1 (ko)
BR (1) BRPI0609785B8 (ko)
CA (1) CA2602247C (ko)
CY (2) CY1111206T1 (ko)
DE (1) DE602006019838D1 (ko)
DK (1) DK1869025T6 (ko)
ES (1) ES2358631T7 (ko)
HK (1) HK1112236A1 (ko)
HU (2) HUE011611T6 (ko)
IL (1) IL185909A (ko)
IN (1) IN2012DN00855A (ko)
LT (1) LTC1869025I2 (ko)
LU (1) LUC00086I2 (ko)
MY (1) MY142746A (ko)
NL (1) NL300946I2 (ko)
PL (1) PL1869025T6 (ko)
PT (1) PT1869025E (ko)
SI (1) SI1869025T1 (ko)
TW (1) TWI320783B (ko)
WO (1) WO2006112464A1 (ko)
ZA (1) ZA200708686B (ko)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
USRE45337E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US8148417B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
MX2008014622A (es) 2006-05-18 2008-11-28 Arena Pharm Inc Formas cristalinas y procesos para la preparacion de fenil-pirazoles utiles como moduladores del receptor de serotonina 5-ht2a.
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
WO2008047883A1 (en) * 2006-10-13 2008-04-24 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
WO2009101018A2 (en) * 2008-02-15 2009-08-20 F. Hoffmann-La Roche Ag 3-alkyl-piperazine derivatives and uses thereof
JP5404652B2 (ja) 2008-02-22 2014-02-05 アクテリオン ファーマシューティカルズ リミテッド オキサゾリジノン誘導体
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
HUE036506T2 (hu) 2008-10-28 2018-07-30 Arena Pharm Inc 5-HT2A szerotonin receptor modulátort tartalmazó készítmények az ilyen receptor modulátorokkal kapcsolatos rendellenességek kezelésére
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CA2766088C (en) 2009-06-25 2017-06-13 Alkermes, Inc. Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
JP5857040B2 (ja) 2010-05-04 2016-02-10 アルカーメス ファーマ アイルランド リミテッド 酸化ラクタム化合物の合成方法
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JOP20120083B1 (ar) 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
TWI546299B (zh) * 2011-07-28 2016-08-21 大塚製藥股份有限公司 用於製造苯并［ｂ］噻吩之方法
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI679977B (zh) * 2011-10-19 2019-12-21 大塚製藥股份有限公司 口服溶液
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AU2013259551B2 (en) * 2012-05-09 2017-11-02 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
EP2792359A1 (en) * 2013-04-19 2014-10-22 Merz Pharma GmbH & Co. KGaA Treatment of L-DOPA-induced dyskinesia with OPC-14523 or OPC-34712
KR101472916B1 (ko) 2013-06-27 2014-12-16 한국과학기술연구원 모르폴린 또는 피페라진 화합물, 및 도네페질을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN104557896A (zh) 2013-10-18 2015-04-29 沈敬山 布瑞哌唑、其关键中间体及其盐的制备方法
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
TW201625252A (zh) 2014-04-22 2016-07-16 大塚製藥股份有限公司 藥物
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN105461703B (zh) * 2014-12-29 2019-05-17 深圳市泛谷药业股份有限公司 一种brexpiprazole的制备方法
CN105985314A (zh) * 2015-02-05 2016-10-05 苏州旺山旺水生物医药有限公司 布瑞哌唑类似物的制备方法
CN104844586A (zh) * 2015-04-16 2015-08-19 重庆医药工业研究院有限责任公司 一种依匹哌唑无定型物及其制备方法
CN104829588B (zh) * 2015-04-30 2017-03-29 苏州苏旺森生物医药科技有限公司 一种苯并[b]噻吩的制备方法及其中间体
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
JP2018520187A (ja) 2015-07-15 2018-07-26 アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
CN105061414B (zh) * 2015-07-21 2019-01-01 杭州新博思生物医药有限公司 一锅法制备Brexpiprazole
WO2017025987A1 (en) 2015-08-11 2017-02-16 Mylan Laboratories Limited Process for the preparation of brexpiprazole
EP3150591A1 (en) 2015-10-02 2017-04-05 Crystal Pharma S.A.U Process and intermediates for the preparation of benzo[b]thiophene compounds
CN106749219A (zh) * 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
CN105440026A (zh) * 2015-12-04 2016-03-30 上海勋和医药科技有限公司 依匹哌唑的制备方法
CN105461704A (zh) * 2015-12-15 2016-04-06 南京艾德凯腾生物医药有限责任公司 一种依匹哌唑的制备方法
WO2017106641A1 (en) 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
CN106916148B (zh) * 2015-12-25 2021-07-06 上海科胜药物研发有限公司 一种合成依匹哌唑的方法
EP3397636B1 (en) * 2015-12-28 2021-08-04 Honour (R&D) Process for the preparation of quinoline-2(1h)-one derivatives
CN106938982A (zh) * 2016-01-05 2017-07-11 连云港皓海医药科技有限公司 布瑞哌唑的制备方法及用于制备布瑞哌唑的化合物
CN105399736B (zh) * 2016-01-07 2018-10-19 安徽省逸欣铭医药科技有限公司 一种依匹哌唑新的制备方法
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (zh) 2016-05-12 2017-11-21 上海奥博生物医药技术有限公司 一种依匹哌唑新晶型及其制备方法
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
WO2017216661A1 (en) 2016-06-17 2017-12-21 Jubilant Generics Limited Process for the preparation of brexpiprazole from 7-(4-chlorobutoxy)quinolin-2(1h)-one and 1-(benzo[b]thiophen-4-yl)piperazine
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
US11123300B2 (en) 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
US20200093821A1 (en) 2016-08-16 2020-03-26 Hexal Ag Pharmaceutical Compositions of a Benzothiophene Compound
WO2018060916A1 (en) * 2016-09-28 2018-04-05 Alembic Pharmaceuticals Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107936005A (zh) * 2016-10-13 2018-04-20 上海科胜药物研发有限公司 一种依匹哌唑新晶型ii及其制备方法
US11279696B2 (en) 2016-11-09 2022-03-22 Msn Laboratories Private Limited Processes for the preparation of 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one
CN106699745A (zh) * 2016-12-14 2017-05-24 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
EP3577111A1 (en) 2017-02-02 2019-12-11 Hexal Aktiengesellschaft Crystalline brexpiprazole
WO2018172463A1 (en) 2017-03-22 2018-09-27 Amneal Pharmaceuticals Company Gmbh Process for the preparation of brexpiprazole
WO2019073481A1 (en) * 2017-10-12 2019-04-18 Indoco Remedies Limited PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE AND ITS INTERMEDIATES
KR20200099154A (ko) 2017-12-14 2020-08-21 하. 룬드벡 아크티에셀스카브 1H-피라졸로[4,3-b]피리딘의 투여를 포함하는 조합 치료제
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
CN109988162A (zh) * 2017-12-29 2019-07-09 武汉兴华智慧医药科技有限公司 一种依匹哌唑衍生物及其制备方法
EP3545950A1 (en) 2018-03-26 2019-10-02 Adamed sp. z o.o. Pharmaceutical composition comprising brexpiprazole
CN110627777B (zh) * 2018-06-21 2021-01-26 中国科学院上海药物研究所 一种苯并噻吩化合物的马来酸盐、其结晶形式及其用途
CN108947990A (zh) * 2018-07-20 2018-12-07 成都苑东生物制药股份有限公司 一种苯并噻吩类化合物的制备方法
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
CN111320619A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物的杂质及用途
CN109970705B (zh) * 2019-05-14 2021-02-09 浙江工业大学 一种应用廉价金属铜制备依匹哌唑中间体及依匹哌唑的方法
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
EP4132646A1 (en) * 2020-04-08 2023-02-15 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2022010937A1 (en) * 2020-07-06 2022-01-13 Tactogen Inc Advantageous benzothiophene compositions for mental disorders or enhancement
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN114181202A (zh) * 2021-12-17 2022-03-15 湖南省湘中制药有限公司 一种依匹哌唑的制备方法
CN118580229A (zh) * 2024-08-07 2024-09-03 湖南一格制药有限公司 布瑞哌唑的制备方法

Citations (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910955A (en) 1970-12-21 1975-10-07 Aspro Nicholas Ltd Benzothiophene-ethylamines
US3974280A (en) 1973-12-06 1976-08-10 Ciba-Geigy Corporation Benzothiophenes
US4234585A (en) 1978-06-23 1980-11-18 Boehringer Mannheim Gmbh 1,2-Dihydroquinoline-2-one derivatives
US4234584A (en) 1978-06-06 1980-11-18 Hoechst Aktiengesellschaft Substituted phenylpiperazine derivatives
JPS5646812A (en) 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS56164186A (en) 1980-05-21 1981-12-17 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4455422A (en) 1980-03-06 1984-06-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and pharmaceutical composition containing the same
US4621077A (en) 1982-04-15 1986-11-04 Istituto Gentili S.P.A. Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom
US4704390A (en) 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
US4734416A (en) 1978-03-30 1988-03-29 Otsuka Pharmaceutical Co., Ltd. Pharmaceutically useful carbostyril derivatives
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4847254A (en) 1987-02-26 1989-07-11 H. Lundbeck A/S CNS affecting 5-oxy-3-aminomethyl-dihydro-benzofurans and benzothiophenes
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
EP0367141A2 (en) 1988-10-31 1990-05-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
EP0512525A1 (en) 1991-05-08 1992-11-11 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist
WO1994006789A1 (en) 1992-09-17 1994-03-31 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
US5424313A (en) 1984-12-21 1995-06-13 Duphar International Research B.V. Bibyclic heteroacrylpiperazine derivatives having psychotropic activity, and pharmaceutical compositions containing these derivatives
EP0699675A2 (en) 1994-09-01 1996-03-06 Hoechst-Roussel Pharmaceuticals Incorporated 3-(4-(1-Substituted-4-piperazinyl)butyl)-4-thiazolidinone and related compounds
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
WO1996022290A1 (en) 1995-01-17 1996-07-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
EP0732332A1 (en) 1995-03-17 1996-09-18 Hoechst Marion Roussel, Inc. Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
WO1996041802A1 (fr) 1995-06-09 1996-12-27 Pierre Fabre Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments
WO1998007703A1 (fr) 1996-08-22 1998-02-26 Meiji Seika Kaisha, Ltd. Derives quinoleine et agent psychotrope
US5753661A (en) 1992-12-09 1998-05-19 H. Lundbeck A/S Fused benzo compounds containing a nitrogen heterocycle for the treatment of central nervous system disorders
FR2761068A1 (fr) 1997-03-20 1998-09-25 Synthelabo Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
JPH11147871A (ja) 1997-09-02 1999-06-02 Duphar Internatl Res Bv 新規なピペラジン化合物
US5919485A (en) 1995-03-24 1999-07-06 Eli Lilly And Company Oral 2-methyl-thieno-benzodiazepine formulation
US5958924A (en) 1995-09-15 1999-09-28 Synthelabo Quinolein-2 (1H)-one derivatives as serotonin antagonists
US5977110A (en) 1995-09-22 1999-11-02 Warner-Lambert Company Substituted cyclohexylamines as central nervous systems agents
EP0982304A1 (en) 1998-06-30 2000-03-01 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems
WO2000071517A1 (fr) 1999-05-24 2000-11-30 Mitsubishi Pharma Corporation Compose de phenoxypropylamine
US6187340B1 (en) 1997-09-10 2001-02-13 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical preparation
US6225312B1 (en) 1996-03-29 2001-05-01 Duphar International Research B.V. Piperazine and piperidine compounds
WO2001046179A1 (en) 1999-12-20 2001-06-28 Eli Lilly And Company Piperidine derivatives and their use as serotonin receptor antagonists
US6262056B1 (en) 1997-07-08 2001-07-17 Vita-Invest, Sa Benzothiophene derivatives and corresponding use and composition
WO2002044170A2 (en) 2000-11-29 2002-06-06 Laboratorios Vita, S.A. Benzothiophene derivative compounds, process of preparation and use thereof
WO2002066469A2 (en) 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
US20020173513A1 (en) 2001-01-29 2002-11-21 Shaun Jordan 5HT1a Receptor subtype agonist
US20030050306A1 (en) 1999-12-30 2003-03-13 H. Lundbeck A/S Novel heteroaryl derivatives, their preparation and use
WO2003026659A1 (en) 2001-09-25 2003-04-03 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US6596722B2 (en) 1999-01-22 2003-07-22 H. Lundbeck A/S Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use
US20030153617A1 (en) 2001-12-18 2003-08-14 Dalen Frans Van Simvastatin dosage forms
US20040014972A1 (en) 2000-09-05 2004-01-22 Rudolf Gottschlich Arylpiperazine derivatives and their use as psychotropic agents
WO2004026864A1 (en) 2002-09-17 2004-04-01 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004029948A1 (de) 2002-09-20 2004-04-08 Osram Opto Semiconductors Gmbh Optischer abtastkopf und verfahren zur herstellung desselben
WO2004029048A1 (en) 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004060374A1 (en) 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
WO2004063162A1 (en) 2003-01-09 2004-07-29 Otsuka Pharmaceutical Co., Ltd. Process for preparing aripiprazole
US20040175422A1 (en) 2001-05-25 2004-09-09 Yuso Tomohira Medicinal composition
EP1204660B1 (en) 1999-07-29 2004-10-20 Eli Lilly And Company Serotonergic benzothiophenes
WO2004105682A2 (en) 2003-05-23 2004-12-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
US20050004309A1 (en) 2001-10-23 2005-01-06 Matthias Gerst Thermally curable binding agents
US20050043309A1 (en) 2003-08-22 2005-02-24 Clark Jerry D. [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US20050043325A1 (en) 2003-04-29 2005-02-24 Pfizer Inc Novel pharmaceuticals
WO2006097344A1 (en) 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
WO2007065448A1 (en) 2005-09-08 2007-06-14 H. Lundbeck A/S Stable solid formulation of sertindole
US20070154544A1 (en) 2006-01-05 2007-07-05 Julia Hrakovsky Wet formulations of aripiprazole
US20080187582A1 (en) 2005-03-01 2008-08-07 Patrice Guitard Pharmaceutical Composition Comprising an Indolylmaleimide Derivative
US20100013059A1 (en) 2008-07-15 2010-01-21 Taiwan Semiconductor Manufacturing Company, Ltd. Diffusion region routing for narrow scribe-line devices
WO2010052727A1 (en) 2008-11-04 2010-05-14 Ideal Cures Private Limited High performance film coating compositions
US20100130569A1 (en) 2007-05-11 2010-05-27 Saten Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
US20100179322A1 (en) 2005-04-14 2010-07-15 Hiroshi Yamashita Piperazine-substituted benzothiophenes for treatment of mental disorders
US20140234417A1 (en) 2011-10-14 2014-08-21 Otsuka Pharmaceutical Co., Ltd. Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
US9206169B2 (en) * 2011-07-28 2015-12-08 Otsuka Pharmaceutical Co., Ltd. Method for producing benzo[b]thiophene compound
US9260420B2 (en) * 2011-09-08 2016-02-16 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophene derivatives as antipsychotic agents
US9499525B2 (en) * 2012-04-23 2016-11-22 Otsuka Pharmaceutical Co., Ltd. Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1154105A (zh) * 1994-06-08 1997-07-09 H·隆德贝克有限公司 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物

Patent Citations (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910955A (en) 1970-12-21 1975-10-07 Aspro Nicholas Ltd Benzothiophene-ethylamines
US3974280A (en) 1973-12-06 1976-08-10 Ciba-Geigy Corporation Benzothiophenes
US4734416A (en) 1978-03-30 1988-03-29 Otsuka Pharmaceutical Co., Ltd. Pharmaceutically useful carbostyril derivatives
US4824840A (en) 1978-03-30 1989-04-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and pharmaceutical preparations containing same
US4234584A (en) 1978-06-06 1980-11-18 Hoechst Aktiengesellschaft Substituted phenylpiperazine derivatives
US4234585A (en) 1978-06-23 1980-11-18 Boehringer Mannheim Gmbh 1,2-Dihydroquinoline-2-one derivatives
JPS5646812A (en) 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4455422A (en) 1980-03-06 1984-06-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and pharmaceutical composition containing the same
JPS56164186A (en) 1980-05-21 1981-12-17 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4621077A (en) 1982-04-15 1986-11-04 Istituto Gentili S.P.A. Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom
US5424313A (en) 1984-12-21 1995-06-13 Duphar International Research B.V. Bibyclic heteroacrylpiperazine derivatives having psychotropic activity, and pharmaceutical compositions containing these derivatives
US4704390A (en) 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
US4847254A (en) 1987-02-26 1989-07-11 H. Lundbeck A/S CNS affecting 5-oxy-3-aminomethyl-dihydro-benzofurans and benzothiophenes
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
EP0367141A2 (en) 1988-10-31 1990-05-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
EP0512525A1 (en) 1991-05-08 1992-11-11 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
JPH08501559A (ja) 1992-09-17 1996-02-20 メレルダウファーマス−ティカルズ インコーポレイテッド セロトニン受容体剤
WO1994006789A1 (en) 1992-09-17 1994-03-31 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
US5753661A (en) 1992-12-09 1998-05-19 H. Lundbeck A/S Fused benzo compounds containing a nitrogen heterocycle for the treatment of central nervous system disorders
US6140331A (en) 1992-12-09 2000-10-31 H. Lundbeck A/S Fused benzo compounds for the treatment of central nervous system disorders
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
EP0699675A2 (en) 1994-09-01 1996-03-06 Hoechst-Roussel Pharmaceuticals Incorporated 3-(4-(1-Substituted-4-piperazinyl)butyl)-4-thiazolidinone and related compounds
WO1996022290A1 (en) 1995-01-17 1996-07-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
EP0732332A1 (en) 1995-03-17 1996-09-18 Hoechst Marion Roussel, Inc. Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
US5919485A (en) 1995-03-24 1999-07-06 Eli Lilly And Company Oral 2-methyl-thieno-benzodiazepine formulation
WO1996041802A1 (fr) 1995-06-09 1996-12-27 Pierre Fabre Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments
US5958924A (en) 1995-09-15 1999-09-28 Synthelabo Quinolein-2 (1H)-one derivatives as serotonin antagonists
US5977110A (en) 1995-09-22 1999-11-02 Warner-Lambert Company Substituted cyclohexylamines as central nervous systems agents
US6225312B1 (en) 1996-03-29 2001-05-01 Duphar International Research B.V. Piperazine and piperidine compounds
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
WO1998007703A1 (fr) 1996-08-22 1998-02-26 Meiji Seika Kaisha, Ltd. Derives quinoleine et agent psychotrope
EP0934932A1 (en) 1996-08-22 1999-08-11 Meiji Seika Kabushiki Kaisha Quinoline derivatives and psychotropic agent
FR2761068A1 (fr) 1997-03-20 1998-09-25 Synthelabo Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique
US6262056B1 (en) 1997-07-08 2001-07-17 Vita-Invest, Sa Benzothiophene derivatives and corresponding use and composition
US6214829B1 (en) 1997-09-02 2001-04-10 Duphar International Research B.V. Piperazine compounds, their preparation, and methods of using them
JPH11147871A (ja) 1997-09-02 1999-06-02 Duphar Internatl Res Bv 新規なピペラジン化合物
US6187340B1 (en) 1997-09-10 2001-02-13 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical preparation
EP0982304A1 (en) 1998-06-30 2000-03-01 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems
EP0982304B1 (en) 1998-06-30 2002-10-02 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems
US6596722B2 (en) 1999-01-22 2003-07-22 H. Lundbeck A/S Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use
US6720320B2 (en) 1999-05-24 2004-04-13 Mitsubishi Pharma Corporation Phenoxypropylamine compounds
WO2000071517A1 (fr) 1999-05-24 2000-11-30 Mitsubishi Pharma Corporation Compose de phenoxypropylamine
EP1188747A1 (en) 1999-05-24 2002-03-20 Mitsubishi Pharma Corporation Phenoxypropylamine compounds
EP1204660B1 (en) 1999-07-29 2004-10-20 Eli Lilly And Company Serotonergic benzothiophenes
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
WO2001046179A1 (en) 1999-12-20 2001-06-28 Eli Lilly And Company Piperidine derivatives and their use as serotonin receptor antagonists
US20030050306A1 (en) 1999-12-30 2003-03-13 H. Lundbeck A/S Novel heteroaryl derivatives, their preparation and use
US20040014972A1 (en) 2000-09-05 2004-01-22 Rudolf Gottschlich Arylpiperazine derivatives and their use as psychotropic agents
WO2002044170A2 (en) 2000-11-29 2002-06-06 Laboratorios Vita, S.A. Benzothiophene derivative compounds, process of preparation and use thereof
US20020173513A1 (en) 2001-01-29 2002-11-21 Shaun Jordan 5HT1a Receptor subtype agonist
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
WO2002066469A2 (en) 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
US20040175422A1 (en) 2001-05-25 2004-09-09 Yuso Tomohira Medicinal composition
WO2003026659A1 (en) 2001-09-25 2003-04-03 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US20050004309A1 (en) 2001-10-23 2005-01-06 Matthias Gerst Thermally curable binding agents
US20030153617A1 (en) 2001-12-18 2003-08-14 Dalen Frans Van Simvastatin dosage forms
WO2004026864A1 (en) 2002-09-17 2004-04-01 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
US20040138230A1 (en) 2002-09-17 2004-07-15 Andreana Tonja Lynn Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004029948A1 (de) 2002-09-20 2004-04-08 Osram Opto Semiconductors Gmbh Optischer abtastkopf und verfahren zur herstellung desselben
WO2004029048A1 (en) 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004060374A1 (en) 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
WO2004063162A1 (en) 2003-01-09 2004-07-29 Otsuka Pharmaceutical Co., Ltd. Process for preparing aripiprazole
US20050043325A1 (en) 2003-04-29 2005-02-24 Pfizer Inc Novel pharmaceuticals
WO2004105682A2 (en) 2003-05-23 2004-12-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
US20050043309A1 (en) 2003-08-22 2005-02-24 Clark Jerry D. [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2005019215A1 (en) 2003-08-22 2005-03-03 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US20080187582A1 (en) 2005-03-01 2008-08-07 Patrice Guitard Pharmaceutical Composition Comprising an Indolylmaleimide Derivative
WO2006097344A1 (en) 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
US9480686B2 (en) * 2005-04-14 2016-11-01 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
US20100179322A1 (en) 2005-04-14 2010-07-15 Hiroshi Yamashita Piperazine-substituted benzothiophenes for treatment of mental disorders
US8349840B2 (en) * 2005-04-14 2013-01-08 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
US8618109B2 (en) * 2005-04-14 2013-12-31 Otsuka Parmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
US9839637B1 (en) * 2005-04-14 2017-12-12 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
US20170231983A1 (en) 2005-04-14 2017-08-17 Otsuka Pharmaceutical Co., Ltd. Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
US9206167B2 (en) * 2005-04-14 2015-12-08 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
WO2007065448A1 (en) 2005-09-08 2007-06-14 H. Lundbeck A/S Stable solid formulation of sertindole
WO2007081366A1 (en) 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Wet granulation pharmaceutical compositions of aripiprazole
US20070154544A1 (en) 2006-01-05 2007-07-05 Julia Hrakovsky Wet formulations of aripiprazole
US20100130569A1 (en) 2007-05-11 2010-05-27 Saten Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
US20100013059A1 (en) 2008-07-15 2010-01-21 Taiwan Semiconductor Manufacturing Company, Ltd. Diffusion region routing for narrow scribe-line devices
WO2010052727A1 (en) 2008-11-04 2010-05-14 Ideal Cures Private Limited High performance film coating compositions
US9206169B2 (en) * 2011-07-28 2015-12-08 Otsuka Pharmaceutical Co., Ltd. Method for producing benzo[b]thiophene compound
US9260420B2 (en) * 2011-09-08 2016-02-16 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophene derivatives as antipsychotic agents
US9539252B2 (en) * 2011-09-08 2017-01-10 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophene derivatives as antipsychotic agents
US20140234417A1 (en) 2011-10-14 2014-08-21 Otsuka Pharmaceutical Co., Ltd. Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
US9499525B2 (en) * 2012-04-23 2016-11-22 Otsuka Pharmaceutical Co., Ltd. Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Non-Patent Citations (129)

* Cited by examiner, † Cited by third party
Title
Abilify (Aripiprazole) Tablets, NDA 21-436, Drug Approval Package, Pharmacology/Toxicology Review (Mar. 7, 2003). https://www.accessdata.fda.gov/drugsatfda docs/nda/2002/21-436 Abilify.cfm.
Abilify® Label 2002.
Abilify® Label 2003 (revised Aug. 2003).
Abilify® Label 2004.
Abilify® Label 2005.
Abilify® Label 2009.
Abilify® Tablets Prescribing Information, Physicians' Desk Reference 58:1034 (2004).
Aihara et al., The Novel Antipsychotic Aripiprazole is a Partial Agonist at Short and Long Isoforms of D2 Receptors Linked to the Regulation of Adenylyl Cyclase Activity and Prolactin Release, Brain Research, 1003:9-17 (2004).
Arribas et al., Synthesis and Pharmacological Study of the Thiophene Analogue of Taclamine, QM-7184, a New Neuroleptic Drug with Potent α-Adrenoceptor Blocking Activity, Arzneimitel-Forchung Drug Res., 33(10):1417-1421 (1983).
Bandelin, Compressed Tablets by Wet Granulation, Pharmaceutical Dosage Forms, 1:131-193 (1989).
Bandelow and Meier, Aripiprazole, a ‘Dopamine-Serotonin System Stabilizer’ in the Treatment of Psychosis, German J. Psychiatry, 6:9-16 (2003).
Banno et al., Studies on 2(1H)-Quinoline Derivatives as Neuroleptic Agents. I. Synthesis and Biological Activites of (4-Phenyl-1-piperaziny1)-propoxy-2(1H)-quinolinone Derivatives, Chem. Pharm. Bull., 36(11):4377-4388 (1988).
Bantick et al, The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?, Journal of Psychopharmacology, 15(1):37-46 (2001) 2653-2656 (2004).
Barreiro et al., Design, Synthesis, and Pharmacological Profile of Novel Fused Pyrazolo[4,3-d]pyridine and Pyrazolo[3,4-b][1,8]naphthyridine Isosteres: A New Class of Potent and Selective Acetylcholinesterase Inhibitors, J. Med. Chem., 46:1144-1152 (2003).
Belliotti et al., Novel Cyclohexyl Amides as Potent and Selective D3 Dopamine Receptor Ligands, Bioorganic & Med. Chem. Lttrs., 7(18): 2403-2408 (1997).
Bettinetti et al., Interactive SAR studies: Rational discovery of Super-Potent and Highly Selective Dopamine D3 Receptor Antagonists and Partial Agonists, J. Med. Chem. 45(21):4594-4597 (2002).
Blier et al., Potential Mechanisms of Action of Atypical Antipsychotic Medications in Treatment-Resistant Depression and Anxiety, J. Clin. Psychiatry; 66(Suppl. 8): 30-40 (2005).
Bosin, Biologically Active Benzo[b] thiophene Derivatives, II, Advances in Drug Research, 11:191-232 (1977).
Bromidge et al., 5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): A Potent, Selective, and Orally Bioavailable 5-HT6 Receptor Antagonist, J. Med. Chem., 42(2):202-5 (1999).
Bromidge et al., Novel (4-Piperazin-1-ylquinolin-6-yl) Arylsulfonamides with High Affinity and Selectivity for the 5-HT6 Receptor, J. Bioorganic & Medicinal Chemistry Letters 11:2843-2846 (2001).
Burgers Medicinal Chemistry 6th Ed. (2003).
Burke et al., 1Tardive Akathisia: An Analysis of Clinical Features and Response to Open Therapeutic Trials, Movement Disorders 4(2):157-175 (1989).
Burris, Aripiprazole, A Novel Antipsychotic, Is a High-Affinity Partial Against at Human Dopamine D2 Receptors, JPET, 302:381-389 (2002).
Caccia, In-vivo Metabolism of 4-Substituted Arylpiperazines to Pharmacologically Active 1-Arylpiperazines, Boll. Chim. Farmaceutico 129:183 (1990).
Campaigne, et al., The Sulfur Analogue of Serotonin, J. Med.Chem. 10(2):270-1 (1967).
Carroll and Carlezon, Jr., Development of κ Opioid Receptor Antagonists, J. Med. Chem., 56: 2178-2195 (2013).
Chakrabarti et al., 4-Piperazinyl-10H-thieno[2,3- b] [1,5]benzodiazepines as Potential Neuroleptics, J. Med. Chem., 23:878-884 (1980).
Chakrabarti et al., Effects of Conformationally Restricted 4-Piperazinyl-I0H-thienobenzodiazepine Neuroleptics on Central Dopaminergic and Cholinergie Systems1, J. Med. Chem., 25:1133-40 (1982).
Davies et al., Aripiprazole: A Novel Atypical Antipsychotic Drug with a Uniquely Robust Pharmacology, CNS Drug Reviews, 10:317-36 (2004).
Dhawan et al., International Union of Pharmacology, XII, Classification of Opioid Receptorsa, Pharmacological Reviews, 48(4):567-592(1996).
Drugs@FDA, Abilify™ Tablets, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&AppINo=0.21436, downloaded Sep. 17, 2019.
FDA Guidance for Industry: Q1B Photostability Testing of New Drug Substances and Products (1996).
Fura et al., Discovering Drugs through Biological Transformation: Role of Pharmacologically Active Metabolites in Drug Discovery, J. Med. Chem., 47(18):4339-4351 (2004).
Gardner et al., Modern Antipsychotic Drugs: A Critical Overview, CMAJ 172(13):1703-11 (2005).
Goff, Brexpiprazole: A New Antipsychotic Following in the Footsteps of Aripiprazole, Am. J. Psychiatry, 172:820-21 (2015).
Green, Focus on Aripiprazole, Curr. Med. Res. Opin., 20(2):207-13 (2004).
Gronowitz, Thiophene and Its Derivatives Part Five, John Wiley & Sons, Inc. (1992).
Handbook of Pharmaceutical Excipients, Raymond Rowe 4th Ed. (2003).
Handbook of Pharmaceutical Excipients, Raymond Rowe 6th Ed. (2009).
Harrison et al., "Aripiprazole: A Review of Its Use in Schizophrenia and Schizoaffective Disorder", ADIS Drug Evaluation, Drugs, vol. 64, No. 15, pp. 1715-1736, (2004).
He et al., Synthesis and Biological Evaluation of 1-[1-(2-Benzo[b]thienyl)cyclohexyl]piperidine Homologues at Dopamine-Uptake and Phencyclidine—and σBinding Sites, J. Med. Chem., 36:1188-1193 (1993).
Heinrich et al., Synthesis and Structure-Activity Relationship in a Class of Indolebutylpiperazines as Dual 5-HT1A Receptor Agonists and Serotonin Reuptake Inhibitors, J. Med. Chem., 47:4684-4692 (2004).
Hicks, The Effect of Serotonergic Agents on Haloperidol-Induced Catalepsy, Life Sciences, 47:1609-1615 (1990).
Highlights of Prescribing Information—Risperdal (2009).
Hirose et al., Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile, J. Psychopharm., 18(3):375-83 (2004).
Howard, Antipsychotic drugs: recent developments and novel agents, Exp. Opin. Ther. Patents, 7(4):353-369 (1997).
Hrib et al., Structure-Activity Relationships of a Series of Novel (Piperazinybutyl)thiazolidinone Antipsychotic Agents Related to 3-[4-[4-(6-Flurobenzo[b]thien-3-yl)-l piperazinyl] butyl]-2,5,5-trimethyl-4-thiazolidinone Maleate, J. Med. Chem., 39:4044-4057 (1996).
ICH Harmonised Tripartite Guideline, Dose-Response Information to Support Drug Registration. E4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1994).
ICH Harmonised Tripartite Guideline, Stability Testing: Photostability Testing of New Drug Substances and Products, Q1B, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1996).
Inoue and Nakata, Strategy for Modulation of Central Dopamine Transmission based on the Partial Agonist Concept in Schizophrenia Therapy, Jpn. J. Pharmacol. 86:376-380 (2001).
Ishigooka et al., "Trends in the Clinical Development of the Second Generation Antipsychotics", Rinsho-Seishin-Yakuri, (Japanese Journal of Clinical Psychopharmacology), vol. 4, pp. 1653-1664, (2001).
Jordan et al., The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor, European Journal of Pharmacology, 441:137-140 (2002).
Kane et al., Expert Consensus for Optimizing Pharmacologic Treatment of Psychotic Disorders, J. Clin. Psychiatry, 64(suppl. 12): 5-19 (2003).
Kapur and Remington, Serotonin-Dopamine Interaction and its Relevance to Schizophrenia, Am. J. Psychiatry, 153(4):466-476 (1996).
Keck, Jr. and McElroy, Aripiprazole: A Partial Dopamine D2 Receptor Agonist Antipsychotic, Expert Opin. Investig. Drugs, 12(4):655-662 (2003).
Keltner et al., Aripiprazole: A Third Generation of Antipsychotics Begins?, Perspectives in Psychiatric Care, 38(4): 157-159 (2002).
Kikuchi et al., "Aripiprazole, A Novel Antipsychotic—A Dopamine D2 Partial Agonist", Nou-no-Kagaku, (Brain Science), vol. 25, pp. 579-583, (2003).
Kikumoto et al., Japanese Journal of Psychopharmacology, vol. 12, No. 6, Dec. 1992.
Kikumoto, Osamu et al.; "Catalepsy Eliciting Effect and Effects on Cerebral Dopamine, Serotonin, and Gaba Metabolism of Risperidone in Rats: Comparison With Haloperidol," Japan Journal Psychopharmacol. 13, pp. 39-42 (1993).
Kuipers et al., N4-Unsubstituted N1-Arylpiperazines as High-Affinity 5-HT1A Receptor Ligands, J. Med. Chem., 38:1942-54 (1995).
Kukla & Woo, 5-Chloro-2-phenyl-1-benzo[b]thiophene-3-alkanamines, Potential Antipsychotic Agents, J Med. Chem., 21(4):348-52 (1978).
Kus, Novel Antipsychotic Drugs Approved in 2015: Brexpiprazole, Cariprazine, Aripiprazole Lauroxil, Med. Chem., 6(6):425-428 (2016).
Lamothe, Synthesis of New Benzothienylpiperazine Derivatives and Their Characterisation at Both 5HT1A and 5HT1B Receptor Sites, Med. Chem. Res., 8(3):132-142 (1998).
Law et al., Molecular Mechanisms and Regulation of Opioid Receptor Signaling, Annu. Rev. Pharmacol. Toxicol., 40:389-430 (2000).
Lawler et al., Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes, Neuropsychopharmacology, 20(6):612-627 (1999).
Lin and Lu., Role of Pharmacokinetics and Metabolism in Drug Discovery and Development, Pharmacol. Rev., 49(4):403-449 (1997).
Lopez-Rodriguez et al., Synthesis and Structure-Activity Relationships of a New Model of Arylpiperazines. 5.1 Study of the Physicochemical Influence of the Pharmacophore on 5-HT1A/α1 -Adrenergic Receptor Affinity: Synthesis of a New Derivative with Mixed 5-HT1A/D2 Antagonist Properties+, J. Med. Chem., 44:186-197 (2001).
López-Rodríguez et al., Synthesis and Structure-Activity Relationships of a New Model of Arylpiperazines. 6. Study of the 5-HT1A/α1 -Adrenergic Receptor Affinity by Classical Hansch Analysis, Artificial Neural Networks, and Computational Simulation of Ligand Recognition, J. Med. Chem., 44:198-207 (2001).
Lowe, III et al., 1-Naphthylpiperazine Derivatives as Potential Atypical Antipsychotic Agents, J. Med. Chem., 34:1860-1866 (1991).
Maisonneuve et al., U50,488, a κ Opioid Receptor Agonist, Attenuates Cocaine-induced Increases in Extracellular Dopamine in the Nucleus Accumbens of Rats, Neuroscience Letters, 181:57-60 (1994).
Marona-Lewicka and Nichols, Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats, Psychopharmacology, 172:415-421 (2004).
Martinez et al., New 3-[4-(aryl)-piperazin-l-yl)-1-(benzo[b]thiophen-3-yl) propane derivatives with dual action at 5-HT1A serotonin receptors and serotonin transporters as a new class of antidepressants, Eur. J. Med. Chem., 36:55-61 (2001).
Martinez-Esparza et al., New l-aryl-3-(4-arylpiperazin-l-yl)propane Derivatives, with Dual Action at 5-HT1A Serotonin Receptors and Serotonin Transporter, as a New Class of Antidepressants, J. Med. Chem., 44:418-428 (2001).
Martin-Smith and Reid, Biological Activity in Compounds Possessing Thiophen Rings, J. Med. Pharm. Chem., 1(6):507-564 (1959).
Mayol et al., Metabolism of the Antipsychotic Drug Tiospirone in Humans, Drug Metabolism & Disposition, 19(2):394-399 (1991).
Meltzer et al, "Serotonin Receptors: Their Key Role in Drugs to Treat Schizophrenia", Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 27, pp. 1159-1172, (2003).
Millan, Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors, J. Pharmacol. Exp. Ther., 295(3):853-861 (2000).
Moloney et al., "Synthesis and Serotonergic Activity of Variously Substituted (3-Amido)Phenylpiperazine Derivatives and Benzothiophene-4-Piperazine Derivatives: Novel Antagonists for the Vascular 5-HT1B Receptor", European Journal of Medicinal Chemistry, vol. 39, pp. 305-321, (2004).
Murasaki et al., "The Prospect of New Pharmacological Treatment Against Psychiatric Disorders", Rinsho-Seishin-Yakuri, (Japanese Journal of Clinical Psychopharmacology), vol. 1, pp. 5-22, (1998).
Murasaki et al., Phase I Study of a New Antiphychotic Drug, OPC-4392, Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 12:793-802 (1988).
Nakai et al., Diminished Catalepsy and Dopamine Metabolism Distinguish Aripiprazole from Haloperidol or Risperidone, European Journal of Pharmacology, 472:89-97 (2003).
Norman et al., Synthesis and Evaluation of Heterocyclic Carboxamides as Potential Antipsychotic Agents, J. Med. Chem., 39:4692-4703 (1996).
Oh et al., Serotonin Receptor and Transporter Ligands—Current Status, Current Medicinal Chemistry, 8:999-1034 (2001).
Oshiro et al., "Novel Antipsychotic Agents With Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-Piperazinyl/Butoxy]-3,4-Dihydro-2(1H)-Quinolinone Derivatives", J. Med. Chem., vol. 41, pp. 658-667, (1998).
Ozdemir et al., Aripiprazole (Otsuka Pharmaceutical Co.), Curr. Opin. Investig. Drugs, 3(1):113-20 (2002).
Pacher and Kecskemeti, Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, Old Concerns?, Curr. Pharm. Des., 10:2463-2475 (2004).
Patani and LaVoie, Bioisosterism: A Rational Approach in Drug Design, Chem. Rev., 96:3147-3176 (1996).
Pinder et al, Comparative Pharmacology of 5-Hydroxytryptamine and Its Benzofuran, Ben[b]thiophen, and Indene Isosteres, J. Med. Chem., 14(7):626-628 (1971).
Porter & Bruno, Coating of Pharmaceutical Solid-Dosage Forms, Pharmaceutical Dosage Forms, 3:77-160 (1990).
Preventing and Reversing Weight Gain Associated With Psychiatric Medications by Dr. Candida Fink, available at http://blogs.psychcentral.com/bipolar/2008/10/preventing-and-reversing-w . . . Oct. 31, 2016.
Pullar et al., "LY367265, An Inhibitor of the 5-Hydroxytryptamine Transporter and 5-Hydroxytryptamine2A Receptor Antagonist: A Comparison With the Antidepressant, Nefazodone", European Journal of Pharmacology, vol. 407, pp. 39-46, (2000).
Raj and Mangla, Aripiprazole Induced Severe Parkinsonian Symptoms, Indian J. Psychiatry, 46:174-75 (2004).
Rexulti Label Feb. 2018.
Reynolds, Receptor Mechanisms in the Treatment of Schizophrenia, J Psychopharm., 18(3):340-45 (2004).
Robichaud et al., Chapter2. Recent Advances in Selective Serotonin Receptor Modulation, Annual Reports in Medicinal Chemistry, 35:11-20 (2000).
Rocco et al., Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 4, J. Bioorganic & Med. Chem. Lett., 14:2653-56 (2004).
Roth et al., Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia, Nat. Rev. Drug Discov., 3(4):353-9 (Apr. 2004).
Rummel-Kluge, Christine et al., "Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-Analysis of Head-To-Head Comparisons," Schizophrenia Bulletin, vol. 38, No. 1, pp. 167-177 (2012).
Santana et al., Synthesis and Structure—Activity Relationships of New Arylpiperazines: Para Substitution with Electron-Withdrawing Groups Decrease Binding to 5-HT1A and D2A Receptors, Eur. J. Med. Chem., 37:503-510 (2002).
Search Report for Corresponding Indian Application No. 7041/DELNP/2007 dated Feb. 22, 2011.
Shamblee and Gillespie. Jr., Antimalarials. 4. Trichloronaphthalene Amino Alcohols1, J. Med. Chem., 22(1):86-89 (1979).
Shapiro et al., Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology, Neuropsychopharmacology, 28:1400-1411 (2003).
Silverman, Chap. 2 Drug Discovery, Design, and Development, The Organic Chemistry of Drug Design and Drug Action, 2nd Ed., pp. 7-120 (2004).
Spanagel et al., Opposing Tonically Active Endogenous Opioid Systems Modulate the Mesolimbic Dopaminergic Pathway, Proc. Natl. Acad. Sci. USA, 89:2046-2050 (1992).
Sprouse et al., Comparison of the Novel Antipsychotic Ziprasidone with Clozapine and Olanzapine: Inhibition of Dorsal Raphe Cell Firing and the Role of 5-HT1A Receptor Activation, Neuropsychopharmacologv, 21(5):622-631 (1999).
Stahl, Dopamine System Stabilizers, Aripiprazole and the Next Generation of Antipsychotics, Part I, J. Clin. Psychology, 62(11):841-42 (2001).
Stahl, Dopamine System Stabilizers, Aripiprazole. and the Next Generation of Antipsychotics, Part 2, J Clin. Psychiatry, 62(12):923-924 (2001).
Stahl, Mechanism of Action of Brexpiprazole: Comparison with Aripiprazole, CNS Spectrums, 21:1-6 (2016).
Stetka, Why Don't Animals Get Schizophrenia (and How Come We Do)?, Scientific American online, (Mar. 24, 2015). (found at https://www.scientificamerican.com/article/why-don-t-animalsget-schizophrenia-and-how-come-we-do/).
Svensson, "α-Adrenoceptor Modulation Hypothesis of Antipsychotic Atypicality", Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 27, pp. 1145-1158, (2003).
Swainston-Harrison and Perry, Aripiprazole A Review of its Use in Schizophrenia and Schizoaffective Disorder, Drugs, 64(15):1715-1736 (2004).
Tada, Miho et al., "Combined Treatment of Quetiapine With Haloperidol in Animal Models of Antipsychotic Effect and Extrapyramidal Side Effects: Comparison With Risperidone and Chlorpromazine," Psychopharmacology 176: 94-100 (2004).
Tada, Miho et al., "The Antipsychotic Action in Mice and Influence on Extrapyramidal Symptom Due to Combined Use of Atypical Antipsychotic Medicines, Quetiapine and Haloperidol," J. New Rem. & Clin., vol. 52, No. 10 (2003).
Tatsumi et al., (+)-3[2-(Benzo[b]thiophen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2]—octane as potent agonists for the α7 nicotinic acetylcholine receptor, Bioorganic & Medicinal Chemistry Letters, 14:3781-3784 (2004).
Thoma, Chapter 16 Photostabilization of Solid and Semisolid Dosage Forms, Pharmaceutical Photostability and Stabilization Technology, pp. 323-342 (2007).
Thorma, Chap. 6 Photodecomposition and Stabilization of Compounds in Dosage Forms, Photostability of Drugs and Drug Formulations, pp. 111-140 (1996).
Thornber, Isosterism and Molecular Modification in Drug Design, Chemical Soc'y Revs., 7:563-580 (1978).
Torrey, Two New Antipsychotics: What Do We Know About Them, Research Weekly, at https://www.treatmentadvocacycenter.org/fixing-the-system/features-and-news/3 005-research-weekly-two-new-antipsychotics-what-do-we-know-about-them—(Feb. 2, 2016).
Toru et al., "Creativity in the Development of the Drug, Aripiprazole : A Novel Partial Dopamine D2 Receptor Agonist for the Treatment of Schizophrenia", Seishin-Igaku, (Psychiatry), vol. 46, pp. 855-864, (2004).
U.S. Appl. No. 60/497,370, Johnson et al., filed Aug. 22, 2003.
Van Steen et al., Structure-Affinity Relationship Studies on 5-HT1A Receptor Ligands. 2. Heterobicyclic Phenylpiperazines with N4-Aralkyl Substituents, J. Med. Chem., 37:2761-2773 (1994).
Vann, Newly Approved Rexulti Will Need to Be Differentiated from Predecessor Abilify, CNS Drug News, 358:1 (2015).
Watanabe, Yoshifumi et al., "Syntheses of 4-(Benzo[B]Furan-2 or 3-yl)—and 4-(Benzo[B]-Thiophen-3-yl)Piperidines With 5-HT2 Antagonist Activity," J. Heterocyclic Chem., 30, 445 (1993).
Wesolowska, In the Search for Selective Ligands of 5-HT5, 5-HT6 and 5-HT7 Serotonin Receptors, Polish J. of Pharmacology, 54:327-341 (2002).
Wilson-Gisvold, Chapter 24, Organic Medicinal and Pharmaceutical Chemistry (12th Ed.), pp. 776-818 (2011).
Winans, Formulary Review, Aripiprazole, Am. J. Health-Syst. Pharm., 60(23):2437-45 (2003).
Wu, [1]Benzothiophene-based Potentiators of 5-Hydroxytryptamine, Doctor of Philosophy thesis, Department of Chemistry, University of Wollongong, 1995.
Yagcioglu, Turkish Journal of Psychiatry; vol. 18(4), pp. 1-10 (2007).
Yasuda et al., 7-[3-(4-[2,3-Dimethylphenyl) Piperazinyl)Propoxy}-2(IH)-Quinolinone (OPC-4392), A Presynaptic Dopamine Autoreceptor Agonist and Postsynaptic D2 Receptor Antagonist, Life Sciences, 42:1941-1954 (1988).

Also Published As

Publication number Publication date
US20160051548A1 (en) 2016-02-25
CY1111206T1 (el) 2015-06-11
US20170000786A1 (en) 2017-01-05
US8349840B2 (en) 2013-01-08
HUS1800041I1 (hu) 2018-11-28
EP1869025A1 (en) 2007-12-26
PL1869025T6 (pl) 2017-10-31
LTC1869025I2 (lt) 2019-05-10
EP1869025B3 (en) 2016-08-31
KR20080002817A (ko) 2008-01-04
US20190321359A1 (en) 2019-10-24
HK1112236A1 (en) 2008-08-29
IN2012DN00855A (ko) 2015-07-10
AU2006237905C1 (en) 2015-11-19
WO2006112464A1 (en) 2006-10-26
US7888362B2 (en) 2011-02-15
MY142746A (en) 2010-12-31
US20170231983A1 (en) 2017-08-17
LTPA2018509I1 (lt) 2018-09-10
ZA200708686B (en) 2009-01-28
TW200716619A (en) 2007-05-01
US20200237755A1 (en) 2020-07-30
US8618109B2 (en) 2013-12-31
ES2358631T3 (es) 2011-05-12
US20140163039A1 (en) 2014-06-12
SI1869025T1 (sl) 2011-04-29
AU2006237905A1 (en) 2006-10-26
IL185909A (en) 2014-08-31
CA2602247A1 (en) 2006-10-26
ES2358631T7 (es) 2016-11-17
US9480686B2 (en) 2016-11-01
US20130158044A1 (en) 2013-06-20
ATE496911T3 (de) 2011-02-15
CN101155804A (zh) 2008-04-02
TWI320783B (en) 2010-02-21
NL300946I2 (nl) 2018-09-26
BRPI0609785B1 (pt) 2020-10-20
US20190117648A1 (en) 2019-04-25
CA2602247C (en) 2013-04-02
US9206167B2 (en) 2015-12-08
HUE011611T6 (en) 2017-04-28
DK1869025T6 (da) 2017-01-02
US20100179322A1 (en) 2010-07-15
LUC00086I2 (ko) 2018-11-26
US9839637B1 (en) 2017-12-12
DE602006019838D1 (de) 2011-03-10
BRPI0609785B8 (pt) 2021-05-25
DK1869025T3 (da) 2011-04-04
BRPI0609785A2 (pt) 2010-04-27
AU2006237905B2 (en) 2009-09-03
PL1869025T3 (pl) 2011-06-30
CY2018028I1 (el) 2019-07-10
EP1869025B1 (en) 2011-01-26
US20210113556A1 (en) 2021-04-22
PT1869025E (pt) 2011-02-04
KR100937623B1 (ko) 2010-01-20
CY2018028I2 (el) 2019-07-10
AR053577A1 (es) 2007-05-09
US20110152286A1 (en) 2011-06-23
US20170368060A1 (en) 2017-12-28
IL185909A0 (en) 2008-01-06
CN101155804B (zh) 2013-03-27
US20180214444A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
US9839637B1 (en) Piperazine-substituted benzothiophenes for treatment of mental disorders
JP4315393B2 (ja) 複素環化合物
JP4540700B2 (ja) 医薬
JP4785881B2 (ja) 医薬
WO2008047883A1 (en) Piperazine-substituted benzothiophenes for treatment of mental disorders
AU2010200362A1 (en) Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders
RU2402549C2 (ru) Пиперазин-замещенные бензотиофены для лечения психических расстройств
JP2008115175A (ja) 複素環化合物
JP2014162781A (ja) 複素環化合物
MX2007012626A (es) Benzotiofenos sustituidos con piperazina para el tratamiento de trastornos mentales.

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12